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Abstract          
Nonribosomal peptides are therapeutically important natural products produced 
through pathways that utilize large multimodular enzymes, termed nonribosomal peptide 
synthetases (NRPSs). Central to the assembly line methodology, the monomer building 
blocks and the growing polymer chain are covalently linked to dedicated peptidyl carrier 
protein domains as phosphopantetheinyl thioesters. Although structures of multidomain 
NRPS fragments have been solved recently, the active conformation of the carrier 
domains with their attached phosphopantetheinyl arms has not been determined. 
Significant conformational changes in carrier domains are likely to occur as the domains 
shuttle peptidyl phosphopantetheinyl thioesters between the active sites of the partner 
domains.  
This thesis focuses on the application of the synthetic isosteric non-hydrolyzable 
CoA analogs to manipulate carrier domain geometry of NRPS assemblies through. The 
synthetic conjugates are designed to deliver an inhibitor moiety to a domain of interest.  
Using this strategy, various complexes have been designed to direct the 
phosphopantetheinyl arm to active sites of adenylation domains and thioesterase domains 
in catalytically relevant conformations. The structurally restrained multidomain NRPS 
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assemblies are useful for elucidating the complex structure and mechanism of NRPSs. An 
X-ray crystal structure of a peptidyl carrier-thioesterase NRPS didomain fragment from 
enterobactin synthetase has been solved with an α-chloro-phosphopantetheinyl analog 
which forms a cross-link between the two domains.  This structure provides, for the first 
time, detailed insights into the phosphopantetheinyl arm interaction with an NRPS 
partner domain, as well as an active confirmation of a mutidomain NRPS in the holo-
form. In addition, the hydrolytically stable CoA analogs have been successfully used as 
probes in the structural and mechanistic study of a CoA-utilizing enzyme DpgC, a unique 
cofactor-independent dioxygenase involved in vancomycin biosynthesis.  
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Chapter 1: 
The chemistry and structure of nonribosomal peptide synthetases 
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1.1 Nonribosomal peptides 
Nonribosomal peptides (NRPs) are short peptide natural products produced 
through pathways that utilize large multimodular enzymes (Figure 1).1 NRPs display a 
variety of biological activities, some of which are directly related to cellular metabolism, 
for example, iron-chelation and transport.2 Others are medicinally relevant activities such 
as antibiotic, antitumor, immunosuppressive, or cytotoxic, which allows them to be 
frequently used as therapeutics in modern medicine.3,4 
 
Figure 1: Examples of nonribosomal peptides. 
Nonribosomal peptides display larger structural diversity compared to 
peptides/proteins synthesized by the ribosomal machinery. The ribosome produces amino 
acid polymers (proteins) on the order of 102-103 amino acids in length, but the building 
block composition is limited to the twenty proteinogenic amino acids. The large 
structural diversity of NRPs results from the use of nonproteinogenic amino acids, 
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alternate linkages and complex postsynthetic tailoring reactions, together a predominant 
feature of NRPs (Figure 1).5  
 
1.2 Biosynthesis of nonribosomal peptides 
The biosynthesis of nonribosomal peptides is dependent on enzymes named 
nonribosomal peptide synthetases (NRPSs) arranged mostly in linear assembly line 
manner (Figure 2). NRPSs are composed of multiple modules, about three to five NRPS 
domains responsible for the incorporation of one building block into the growing peptide 
chain.3 Within each module reside minimally three core domains: adenylation (A), 
condensation (C) and peptidyl carrier protein (PCP) with the general exception that 
initiation modules lack C domains and termination modules contain thioesterase (TE) 
domains. 
 NRPS assembly line machinery employs a thiol-templated oligomerization 
mechanism similar to the enzymology used by polyketide and fatty acid synthases.6,7 
During the synthetic pathway, building blocks and intermediates are covalently attached 
to a thiol-terminated phosphopantetheine (Ppant) prosthetic group as thioesters (Figure 
3).3 The flexible Ppant arm is 18 Å in length and derived from coenzyme A. Post-
translational modification of the conserved serine residue on small carrier domains (10-
12 kDa) by phosphopantetheinyl transferase (PPTase) produces the prosthetic group to 
transport and deliver substrates to diverse catalytic domains.8 
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Figure 2: Vancomycin biosynthesis as an example of a nonribosomal peptide synthetase assembly 
line. 
The basic logic of NRPS chemistry is well-established (Figure 2).1,3 The initiation 
step of the oligomerization is the selection and activation of a specific amino acid by A 
domains. Using a similar chemical activation pathway with aminoacyl-tRNA synthetases 
in ribosomal machinery, an A domain consumes ATP to convert the amino acid to an 
aminoacyl-AMP intermediate.9,10 The activated amino acid is then transferred to the 
phosphopantetheine arm tethered to the downstream PCP domain, forming a covalently 
bound thioester adduct. The PCP domain is functionally similar to tRNA as it transports 
the activated amino acid. In the elongation steps, C domains, sharing some analogy in 
function to the elongation site of the ribosome, catalyze peptide bond formation. A 
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condensation domain of the downstream module couples the amino group of donor 
substrate with the upstream thioester, forming the amide bond and releasing a free 
phosphopantetheine arm.11 The resulting peptide grows and is transferred downstream 
along the assembly line machinery by repeating the above process. At the end of the 
elongation process, the mature peptide remains attached to the PCP domain of the last 
module. The C-terminal TE domain cleaves the bound peptide from the machinery by 
hydrolyzing it to a linear carboxylic acid (such as in vancomycin synthesis) or cyclizing it 
to macrocyclic product (like cyclosporin A and surfactin, see Figure 1).  
 
Figure 3: The thiol-terminated phosphopantetheine (Ppant) prosthetic group tethered on PCP 
domain. A) Holo-NRPSs formed from apo-NRPSs with PPTase and CoA. B) The chemical 
representation of the Ppant arm derived from coenzyme A. 
Besides the core domains, NRPSs can include specialized domains to modify the 
peptide intermediates during the chain elongation, such as epimerization (E) domains, 
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heterocyclization (Cy) domains, and methyl transferases (MT) domains etc. E domains 
change the stereochemistry of the α-carbon of the aminoacyl-S-PCPs.12 Cy domains are 
evolutionarily specialized C domains catalyzing both amide bond formation and 
heterocyclization of either Cys, Ser or Thr sidechains to form oxazoline/thiazoline rings 
in growing peptide backbone.13 MT domains use the cofactor S-adenosylmethionine 
(SAM) to catalyze the transfer of the methyl group from SAM to the α-amino (N-MT), 
hydroxyl (O-MT) or the α-carbon (C-MT) of the amino-acyl-S-PCP substrate.14-17 The 
tailoring enzymes, either integral parts of the NRPS acting in cis or distinct enzymes 
acting in trans on the way, contribute to the large structural diversity of NRPs.18-22 
Due to the increasing number of resistant pathogenic bacterial strains, the need for 
new antibiotics or therapeutics is growing. 23 Improving or altering existing antibiotics by 
organic synthesis is a challenge in providing molecules with novel activities.3,24 
Combinatorial genetics has recently been shown to be a promising approach to alter the 
structure of the resultant product rationally to gain new properties.25 For example, by 
swapping the A domain of one of the NRPS modules and making a chimeric assembly-
line enzymes in the nonribosomal synthesis, the selectivity of that A domain could be 
altered towards a different carboxylic acid building block which could bring novel 
activity (Figure 4). This modification would be passed along the NRPS assembly line and 
incorporated into the final NRP product, introducing new properties to the antibiotic 
analog. Based on the specialty code derived from the A domain structures, Eppelmann et 
al successfully altered two A domains’ selectivity by site-directed mutagenesis.26 Nguyen 
et al combined module exchanges, NRPS subunit exchange and inactivation of the 
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tailoring enzyme to produce a library of novel lipopeptides analogous to daptomycin, one 
of which was more potent than daptomycin.27 Fischbach et al demonstrated that the 
impaired enzyme activity could be functionally improved by directed evolution.28  
 
Figure 4: Demonstration of introducing novel properties to NRPs by genetic modification on 
NRPSs. 
A significant limitation of the generic manipulation of biosynthetic machinery is 
that the downstream domains/modules in a NRPS may not recognize or process 
efficiently the modified product resulted from the engineered upstream enzymes.25 
Therefore, understanding the mechanism of individual domains along with 
interdomain/intermodule contact is the key to rationally redesign of NRPSs to create 
novel peptides.  
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1.3 Structure and function of NRPS core-domains 
The X-ray and NMR structures of individual NRPS core domains and three 
multidomain NRPSs29-31 have been determined up to date and are discussed below. The 
structural information has provided valuable insight into the enzymology of these 
complicated assembly line machines, forming a basis for engineering these enzymes to 
develop novel peptide products.  
 
1.3.1 Structure and function of adenylation domains 
The first crystal structure of NRPS adenylation domain is an A domain from the 
gramicidin S synthetase A, GrsA (Figure 5A).32 The structure contains a larger N-
terminal region (AN) with a majority of catalytic functionality and a smaller C-terminal 
subdomain (Ac). Each subdomain of the enzyme shows, respectively, a similar topology 
to the subdomain of the unliganded adenylating enzyme firefly luciferase.33 The 
chemistry of A domains involve two steps (Figure 5B): i) the activation of amino acid or 
carboxylic acid by forming aminoacyl-AMP intermediate with the consumption of ATP; 
ii) the attachment of activated building block onto the thiol-terminated 
phosphopantetheinyl arm of  the adjacent PCP domain. The structure of GrsA allows the 
assignment of selectivity-decisive residues during incorporation of the substrate, and 
leads to the development of a code for predicting A domain selectivity. The crystal 
structure of an aryl acid activating A domain from the bacillibactin biosynthesis, DhbE 
represented that A domains share a similar overall topology and extended the 
nonribosomal code to carboxylic acid-activating A domains.34  
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Structures of several non-NRPS adenylation enzymes have also afforded valuable 
insight into the two-step chemistry of NRPS A domains. 4-Chlorobenzoate-CoA ligase 
bound to substrate and product analogs, respectively, showed two significantly different 
orientations between the N-terminal and C-terminal subdomains.35,36 The enzyme bound 
to a substrate mimic represents a similar orientation to GrsA (Figure 5A top), whereas the 
C-term subdomain rotates by about 140◦ relative to the previous orientation when the 
enzyme is bound to a product analog (Figure 5A lower). This indicates that the relative 
orientation of two subdomains controls the two half reactions catalyzed by A domain. 
 
Figure 5: The crystal structure of an A domain, GrsA and general chemistry catalyzed by A 
domains. A) Two conformations of A domains differing in the orientation of the subdomains. The top 
structure (PDB code, 1 AMU) is proposed to be the conformation corresponding to activating the 
amino acid, while the lower one (PDB code, 13W9) responsible for attaching the amino acid onto the 
phosphopantetheine arm. 
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1.3.2 Structure and function of peptidyl carrier protein domains 
Peptidyl carrier protein domains, with usually 80-100 amino acids, are the 
smallest of the NRPS domains. PCP domains don’t contain any catalytic function but the 
scaffolds for the attachment of the building blocks or the growing peptide chain through 
the phosphopantetheinyl group. This prosthetic group is from the posttranslational 
transfer of coenzyme A to the conserved serine residue in the motif (I/L)GG(D/H)SL.37 
The first NMR structure of an excised PCP domain from the tyrocidine NRPS of B. 
brevis exhibits a four-helix bundle fold with active site serine on a disordered loop by the 
end of the second helix.38 PCPs share a helical bundle fold and the relative position of 
active site serine residue with acyl carrier proteins (ACPs) in polyketide biosynthesis 
machinery, although sequence homology is quite low between them (Figure 6).39,40  
To traffic the substrates/growing peptide chain among the active sites of enzymes 
along the assembly line, a significant amount of domain reorganization is required for the 
assembly line to function. Distinct conformations of PCP domains have been observed 
when changing the state of PCP (holo vs. apo) or added protein binding partners.41 
Recent NMR study of tyrocidine PCP revealed both the apo and holo states of the PCP 
domain each adopt two conformations (Figure 6). A different state (A-state or H-state) is 
unique to each form of the PCP domain and the A/H state is shared between the two. It 
has been demonstrated that conformational diversity is crucial for mobility of the 
phosphopantetheine arm and interaction with in trans partner proteins such as PPTase or 
housekeeping thioessterase TEII. 
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.   
Figure 6: NMR structures of carrier proteins (CP). Three conformations of the PCP domain from 
tyrocidine synthetase (shown in box) and the structure of ACP domain from actinorhodin polyketide 
synthase.  The star symbol presents the positions of the conserved serine residue. The protein ribbon 
representations are ‘rainbow’ colored from red (N-term) to violet. 
 
1.3.3 The structure and function of condensation domains 
C domains are the key entity of NRPSs as they carry out peptide bond formation 
by coupling an amino acyl substrate bound to Ppant arm with the upstream peptidyl 
thioester, transferring the growing chain to the downstream PCP domain. NRPS C 
domains are homologous to acyltransferases, exemplified by chloramphenicol 
acetyltransferase (CAT), which share a conserved HHXXXDG motif.42 The first crystal 
structure of a C domain is from VibH, a stand-alone domain in vibriobactin biosynthesis 
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(Figure 7A). 12 The structure contains a monomeric pseudodimer that is composed of a C-
terminal and an N-terminal half with a deep active site cleft which can accommodate the 
two substrates. The two subdomains of VibH are structurally similar to a CAT 
monomer.42 Surprisingly, a generally conserved histidine important in CAT and in other 
C domains is not crucial for general base catalysis although it is in a favorable 
positioning in the active site.12 The structure of VibH confirmed the active site residues. 
However, as VibH is not an integral NRPS domain, details of the substrate recognition 
and condensation chemistry are not readily apparent. 
 
1.3.4 Structure and function of thioesterase domains. 
TE domains, found at the C-terminus of the last NRPS modules, are responsible 
for the release of the mature peptide products from the assembly line. Product release is 
accomplished by a two-step process which involves the formation of a peptidyl-O-TE-
enzyme intermediate that is next attacked by the internal nucleophile in the peptide or 
external water forming a macrocyclic product43-45 or a linear free acid46, correspondingly. 
TE domains are homologous to the large family of α, β-hydrolases that commonly have a 
catalytic triad of Ser-His-Asp in the active site.47 The first crystal structure of TE domain 
from surfactin synthetase confirmed an α, β-hydrolase fold with a catalytic triad 
embedded in a cavity in the active site (Figure 7B).48 SrfTE was unexpectedly 
crystallized as a dimer composed of one monomer in the closed (C) conformation and the 
other one in the open (O) conformation with the major difference in a flexible ‘lid’ region. 
In the O-conformation, the active site is open to access the substrate, while in the C-
13 
 
conformation, the active site is covered by the lid preventing water from attacking as the 
nucleophile, thereby favoring the cyclization outcome. In addition, the structure of the 
fengycin TE domain shared the overall structural features including a flexible ‘lid’ region 
and a large active site cavity.49   
 
Figure 7: Crystal structures of NRPS  C domain and TE domain. A) X-ray structure of the VibH 
condensation domain B) the TE domain from surfactin synthetase are represented in ribbon format. 
1.3.5 Structural information of multidomain NRPSs  
The structures of individual domains provide valuable insights into the 
enzymology of each step in NRPS assembly line. However, it is equally important to 
understand the domain/domain interactions and the substrate trafficking among the 
domains, which is essential to rationally manipulate NRPSs.  
The first crystal structure of multidomain NRPSs is from an excised apo-PCP-C 
didomain of the tyrocidine synthetase (Figure 8, left).29 The C domain of this construct 
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resembles the stand-alone VibH12, with a V-shaped active site groove. The topology of 
the PCP domain in this didomain structure is alike the A/H state previously described for 
the NMR structure of the stand-alone tyrocidine PCP domain41. However, the two active 
sites of the PCP and C domains are ~50 Å apart, which indicates the PCP-C structure 
corresponds to an orientation prior to peptide transfer from the donor-PCP to the 
acceptor-PCP.  Additionally, structural information along with mutagenesis data and pK 
value analysis of active site residues suggest that peptide bond formation depends on 
electrostatic stabilization of reaction intermediates instead of general acid/base catalysis 
by the HHXXXXD motif previously proposed.12 
 
Figure 8: X-ray crystal structures of didomain NRPSs. The structure of a PCP-C didomain from the 
tyrocidine synthetases (left); the structure of a PCP-TE fragment from enterobaction synthetases (right). 
The location of the active site is indicated by the orange star. 
Frueh et al. reported a NMR structure of a ~37 kDa apo-PCP-TE didomain 
fragment from E. coli enterobactin synthetase, in which the active site Ser of PCP domain 
was replaced with Ala to produce a homogeneous sample in apo-form (Figure 8, right).31 
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The PCP-TE didomain form a compact but dynamic structure with a hydrophobic 
interface between the two domains.  The two active sites are positioned at a suitable 
distance for PCP delivery of substrate into the active site of TE. The TE in this construct 
is structurally similar to the previously described SrfTE structure with a mobile ‘lid’ 
region.48 In addition, extensive interdomain and intradomain motions were observed 
when the didomain interacted with the protein partners, PPTase and the upstream C 
domain. 
The recently solved crystal structure of the four-domain termination module of 
surfactin synthetase (SrfA-C) is the first structure of NRPSs with all the core domains 
evident.30 SrfA-C is responsible for the incorporation of the last building block (L-Leu) 
into the growing peptide and cyclization of the resulting product.  In the 2.6 Å X-ray 
structure (Figure 9), all the individual domains fold similarly to the monomeric structures 
described before. The Ppant arm is absent from the structure as the active site Ser of PCP 
domain is mutated to Ala. The major differences observed in the SrfA-C structure are that 
the hinge region of C domain subdomains is slightly different and the orientation of the 
subdomains of the A domain is not consistent with either the open or closed state 
described previously. The A domain bound to L-Leu in SrfA-C structure is suggested to 
take a conformation before ATP binding. The TE domain is structurally similar to the 
previously described ‘open’ conformation observed in the individual SrfTE.48 The C 
domain and AN subdomain of the A domain form an wide interface that is relatively 
stable during the multiple steps of catalysis. The PCP domain is flexibly tethered to this 
C-A platform so that it can move with its substrate-tethered Ppant arm between the active 
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of the A domain and the donor site of the C domain. The orientation of the PCP domain 
relative to other domains suggests that the SrfA-C crystallized in a conformation where 
the PCP domain interacts with the acceptor site of the C domain.  The four-domain NRPS 
structure has provided the structural basis for the construction of chimeric NRPS proteins. 
 
Figure 9: Crystal structure of a four-domain termination module of surfactin synthetase. A cartoon 
diagram of the relative domain structure is illustrated at the right of the two views.  
 
1.4  A strategy of rational manipulation of PCP domain geometry in NRPSs 
Although several structures of multidomain NRPS fragments have been solved 
recently, the active conformation of the carrier domains with their attached 
phosphopantetheinyl (Ppant) arms has not been determined. Significant conformational 
changes in carrier domains are likely to occur as the domains move peptidyl Ppant 
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thioesters between the active sites of the partner domains. We have developed an 
approach to manipulate carrier domain geometry of NRPS assemblies through the 
application of synthetic isosteric non-hydrolyzable analogs of phosphopantetheinyl 
thioesters (Figure 10).50 Analogs of coenzyme A are loaded on to apo-NRPS proteins 
with PPTase enzymes.  The conjugates are designed to deliver an inhibitor moiety or 
reactive group to a domain of interest.  Using this strategy, various complexes have been 
designed to direct the Ppant arm to the active sites of adenylation domains and 
thioesterase domains in catalytically relevant conformations.50 The structurally restrained 
multidomain NRPS assemblies are useful for elucidating the complex structure and 
mechanism of NRPSs. An X-ray crystal structure of a peptidyl carrier-thioesterase (PCP-
TE) NRPS didomain fragment from enterobactin synthetase has been solved with an α-
chloro-Ppant analog which forms a cross-link between the two domains.51 This 1.9 Å 
resolution structure provides, for the first time, detailed insights into the Ppant arm 
interaction with an NRPS partner domain, as well as an active conformation of a 
mutidomain NRPS in the holo-form. In addition, the hydrolytically stable CoA analogs 
have been successfully used as probes in the structural and mechanistic study of a CoA-
utilizing enzyme DpgC, a unique cofactor-independent dioxygenase involved in 
vancomycin biosynthesis. 52 
18 
 
 
Figure 10: General strategy to form stable complexes of NRPS assemblies with specific carrier 
domain conformation.  A)  Phosphopantetheinyl thioesters in the natural NRPS pathway formed from 
holo-synthetases.  B) Hydrolytically stable, amide analogs of coenzyme A thioesters loaded on to 
NRPS assemblies with the enzyme PPTase. The phosphopantetheinyl analogs are designed with R 
groups that direct the tethered-arm into a specific domain of interest (Dx). C) NRPS-conjugated 
phosphopantetheinyl analogs are synthesized from amino-CoA (1). 
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Chapter 2: 
Synthesis of non-hydrolyzable coenzyme A analogs and analysis of 
loading the analogs on to carrier domains of NRPS. 
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2.1 Introduction 
Coenzyme A (CoA, Figure 1) is a ubiquitous cofactor used as a carrier and 
activator of small molecule intermediates in a wide variety of essential biological 
processes.  Necessary for normal cellular function, CoA plays a central role in fatty 
acid biosynthesis, post-translational modification of proteins, synthesis of secondary 
metabolites, steroid metabolism and numerous other processes.1-4 The terminal thiol 
group of the cofactor condenses with carboxylic acids to form thioesters of diverse 
small molecules.  This thioesterification both activates the acid for downstream 
chemical transformations and provides functionality, 2’,5’ adenosine diphosphate, for 
binding to macromolecules.  The chemistry of CoA is particularly revalent in the 
biosynthetic pathways of secondary metabolites. CoA and the CoA-derived 
phosphopantetheine (Figure 1) are frequently exploited as carriers of growing peptide 
intermediates.5 As mentioned in Chapter 1, this is particularly true for the biosynthetic 
pathways of nonribosomal peptide natural products.  The assembly line methodology 
is dependent on a prosthetic phosphopantetheine arm.6,7 Biosynthetic intermediates in 
the path are shuttled among active sites as phosphopantetheinyl thioesters resulting in 
efficient template-directed synthesis.8   
The study of assembly line methodology requires access to CoA analogs. 
Acyl-CoA substrates and substrate analogs can be synthesized via condensation of 
CoA and a corresponding acid to form a thioester.9 Unfortunately, the hydrolytic 
instability of thioesters at neutral and basic pH can hamper their use as in vitro probes 
for biochemical and structural experiments. The goal of the work described in this 
chapter is to provide a facile and flexible route to stable analogs of acyl-CoA 
thioesters.  These compounds are valuable tools that can be used to probe the 
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chemistry of a variety of CoA-mediated, enzyme-catalyzed reactions. We chose 
amide analogs of CoA thioesters as our synthetic target based on ease of synthesis, 
hydrolytic stability and their close isosteric relationship to thioesters.  The general 
utility of amide analogs of CoA thioesters has been demonstrated in the development 
of analogs of succinyl-CoA.10 Oxy-CoA, which can be converted to acyl ester CoA 
analogs, was also synthesized. Ester analogs were envisioned to be less hydrolytically 
stable relative to the amide versions, but better isosteres of a CoA thioester of interest. 
The value of using analogs of CoA as structural and mechanistic probes has 
been demonstrated in a wide range of enzyme systems. Relevant recent examples 
include the development of thioether analogs of malonyl-CoA designed to trap 
intermediates in Type III polyketide synthases.11 Recent work from Burkart et al. has 
applied a related strategy as outlined here to develop phosphopantetheinyl analogs 
that crosslink domains in fatty acid biosynthetic enzymes.12 
The importance of CoA in enzyme-catalyzed reactions has spurred the 
development of various synthetic approaches toward CoA and its analogs involving 
both chemical and chemoenzymatic routes.13 As outlined in Figure 114, CoA is 
composed of four modules: cystamine (M1), β-alanine (M2) and pantoic acid (M3) 
which is connected to 3’-phosphoadenosine moiety (M4) through a 5’-pyrophosphate 
bridge. In 1961, Moffatt et al. reported the first synthesis of CoA using the coupling 
of pantethenic acid, cystamine (M1) and a 5’-phosphoromorpholidate15, a synthetic 
intermediate that was later improved by Michelson with addition of an adenosine 
diphosphate16. This methodology, starting with pantolactone, is limited by 
racemization at the α-carbon of pantolactone (Figure 1) and low yields limit. 
Therefore, the β-alanine (M2) and pantoic acid (M3) modules are generated together 
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from pantothenate (Figure 1, conventional route). The variation at M2 moiety was 
usually avoided until Mandel et al. reported the modular synthesis of pantetheine 
(Figure1, modular route) .14  
 
Figure 1: A modular view of coenzyme A and the retrosynthetic breakdown to building 
blocks.14 
While there are reports of CoA analogs functionally altered at the thiol 
terminus, these approaches tend to be lengthy or dependent on functionalization of 
thiol-containing CoA or pantetheine as starting materials.17-20 The modular synthesis 
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method of pantetheine developed by Mandel et al. raises the possibility of 
modifications at any of the three building blocks in pantetheine.14 However, the 
synthesis requires multiple chromatographic purification steps and the overall yield is 
only 41% from cystamine or 28% from D-pantolactone. In addition, the pantetheine is 
produced as a disulfide due to the last iodine deprotection step.14 In this chapter, we 
describe a convenient synthesis of amino- and oxy-CoA analogs that can be readily 
converted to stable amide or ester equivalents of acyl-CoA thioesters.  To provide 
ready access to CoA analogs, we chose a combination of solid-phase chemistry and 
chemoenzymatic steps (Figure 2). Our strategy exploits FMOC-based solid-phase 
peptide chemistry to construct the desired pantetheine analogs in two coupling steps.  
To add the highly functionalized 3’-phosphoadenosine moiety, three enzyme-
catalyzed steps using the bacterial CoA biosynthetic machinery are employed to give 
the desired CoA analogs modified at the terminus with an amine or alcohol. 
 
Figure 2: Synthetic strategy of amino-CoA or oxy-CoA. Modules M1-M3 are coupled using 
solid phase synthesis; the rest part of CoA analogs is added by three-step enzymatic reactions 
using bacterial CoA biosynthetic enzymes. 
 
 
 
 31
2.2 Synthesis of amino-CoA analog 
Before coupling the three modules (M1, M2 and M3) together, pantoic acid 
(M3) needs to be protected as the p-methoxyphenyl (PMP) acetal 5. As mentioned 
above, low yield and possible racemization at α-carbon of pantolactone under basic or 
acidic condition makes coupling β-alanine (M2) directly onto D-pantolactone (1) 
inefficient.21 Therefore, we used the approach developed by Shiina et al. for opening 
pantolactone (Figure 3).22 D-pantolactone (1) was reduced with lithium alumimum 
hydride to give triol 2. The 1,3-diol 2 was then selectively protected with p-
anisaldehyde forming the p-methoxyphenyl (PMP) acetal 3. The acetal 3 was oxidized 
subsequently using Swern oxidation conditions and mild chlorite oxidation to afford 
PMP-protected pantoic acid 5. 
 
Figure 3: Synthetic scheme of PMP-protected pantoic acid. 
The solid-phase chemistry used to construct the amino pantetheine analog 8 is 
illustrated in Figure 4.  1,2-Diaminoethane functionalized polystyrene was generated 
by treatment of trityl chloride polystyrene resin with an excess of 1,2-diaminoethane 
in dichloromethane.  One cycle of solid-phase peptide coupling of FMOC-β-alanine 
using PyBOP/DIPEA in NMP followed by deprotection with piperidine gave the 
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chain extended product, 6. Pantoic acid protected as the p-methoxyphenyl (PMP) 
acetal 5 was next coupled to the terminal amine giving the protected pantetheine 
analog 7. Deprotection of the acetal and cleavage from the resin were accomplished in 
one step using trifluoroacetic acid/triethylsilane to yield amino-pantetheine 8 in 70% 
overall isolated yield based on the original loading of the trityl chloride resin. 
Compared to the solution phase method reported by Mandel et al., this solid phase 
approach avoids mutiple chromtographic purification steps, providing a convenient 
way to synthesize pantotheine analogs.23 
 
Figure 4: Solid-phase synthesis of amino-pantetheine analog. 
To install the highly functionalized 3’-phosphoadenosine moiety present in 
CoA, we used the natural biosynthetic enzymes, pantothenate kinase (PanK), 
phosphopantetheine adenylyltransferase (PPAT) and dephosphocoenzyme A kinase 
(DPCK), to convert pantetheine to CoA in three steps all utilizing ATP as a cofactor.2 
It has been shown that each of the three enzymes will tolerate structural alterations at 
the thiol terminus of CoA.24-26 The three enzymes were cloned from E. coli genomic 
DNA using PCR-based cloning strategies and purified (Figure 5). The amino-
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pantetheine analog 8 was then sequentially treated with PanK, PPAT and DPCK in a 
single-pot reaction in the presence of ATP (Figure 6).25 At the reported optimal pH of 
7.5, efficient conversion of substrate with PanK and PPAT was observed, but not with 
DPCK.  It was postulated that the positively charged ammonium in our unnatural 
substrate was impeding the activity of DPCK.  Increasing the pH of the reaction to 9.0 
resolved this issue and allowed efficient conversion by all three enzymes to give 
amino-CoA 11.  The reactions were monitored at 260 nm wavelength by analytic 
reverse-phase HPLC after subsequently adding each enzyme (Figure 7). Both the 
starting material amino-pantetheine 8 and the PanK product, phosphopantetheine 9 
absorb little at 260 nm, while the PPAT product 10 and final product amino-CoA 11 
have large absorbance at that wavelength. The product peaks shift towards earlier 
retention time after each step as the polarity of the product molecules increases. After 
the reactions, the enzymes were removed from the reaction mixture using 
trichloroacetic acid precipitation and the products were purified using reverse-phase 
preparative HPLC to give overall yield of ~50% from amino-pantetheine. 
 
Figure 5: SDS-PAGE analysis of purified PanK, PPAT, DPCK enzymes. 
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Figure 6: Enzymatic conversion of amino-pantetheine analog 8 to amino-CoA analog 11. 
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Figure 5: Analytic HPLC traces of enzymatic preparation of amino-CoA 11. Trace 1, starting 
materials without any enzyme; Trace 2, PanK rxn products; Trace 3, PPAT rxn products; Trace 4, 
DPCK rxn products. 
 
2.2  Synthesis of oxy-CoA 
In addition to the amino-terminated CoA analog 11, the complementary oxy-
CoA analog 13 was synthesized.  This compound can be converted to acyl ester CoA 
analogs. Although ester analogs are less hydrolytically stable relative to the amide 
versions, but they are better isosteres of a CoA thioester of interest.  Our synthesis of 
oxy-CoA, 13 is summarized in Figure 8. The necessary glycinol-functionalized  
starting resin was generated by treatment of 2-chloro trityl chloride polystyrene resin 
with an excess of N-FMOC-ethanolamine in NMP followed by deprotection with 
piperidine.  Two PyBOP-catalyzed coupling steps were then carried out analogous to 
Figure 4 and cleavage/deprotection gave the desired oxy-pantetheine analog 12.  The 
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three-step enzymatic conversion of 12 proceeded smoothly at pH 7.5 to give the 
desired oxy-CoA analog 13.23  
 
Figure 6: Synthesis of hydroxy-functionalized CoA. 
 
2.4 Alternative synthetic route to amino-pantotheine 
Although the solid phase methodology described above provides us a 
convenient access to pantotheine analogs, the synthesis of the precusor PMP-
protected pantoic acid 5 takes four steps to complete. Based on the importance of 
these analogs in biochemical studies, alternative ways have been investigated to avoid 
the synthesis of PMP-protected pantoic acid 5. Pantothenate 14 is potentially a good 
starting material if it could be successfully coupled to the M3 moiety (Figure 1). Due 
to its symmetry, diaminoethane (15, the M3 of amino-pantotheine) doesn’t require 
any protecting group and thus lowers the difficulty of the coupling. Based on these 
assumptions, commercially available pantothenate 14 (as the calcium salt) was 
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coupled to 15 using PyBOP /DIPEA, followed by HPLC purification to afford amino-
pantotheine 8 in the yield of 64%. 
 
Figure 7: Alternative synthetic route to amino-pantotheine 8. 
The limitation of this alternative method lies in the separation of the product 
from PyBOP and starting material. Due to the similarity of the product 8 with PyBOP, 
in terms of polarity, purification on preparative HPLC is not as facile as the solid 
phase. Although the synthetic scale is limited by HPLC purification, starting from 
pantothenate has advantages of skipping four-step synthesis of PMP-protected pantoic 
acid, solid phase coupling and deprotection steps. Therefore, this alternative approach 
provides a shortcut to access amino-pantetheine. 
 
2.5 Analysis of loading non-hydrolyzable coenzyme A analogs on the 
carrier domain of NRPS 
Before using our synthesized non-hydrolyzable CoA analogs to probe the 
chemistry of  CoA-mediated NRPS enzymes, we had to demonstrate these analogs 
could be recognized by PPTase and loaded onto the PCP carrier domains. The E. coli 
NRPS enzyme EntF was used to illustrate our approach of loading amino-conenzyme 
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A analog on PCP domains. EntF is the key NRPS component in the biosynthesis of 
the siderophore enterobactin.27 The 142 kDa enzyme is well-characterized 
biochemically and contains the four core NRPS domains: condensation, adenylation, 
peptidyl carrier protein and thioesterase (Figure 10A). The adenylation domain of the 
module activates the amino acid serine and the thioesterase domain trimerizes and 
cyclizes a 2,3-dihydroxybenzyl-serine thioester.28 More background information of 
EntF will be intoduced in Chapter 3. Synthetic CoA analogs are loaded on apo-EntF 
using the phosphopantetheinyl transferase  (PPTase) from Streptomyces verticillus29. 
The ability of NRPS machinery to directly synthesize the desired amino-acyl 
amide conjugate from amino-CoA 11 and an amino acid was also examined.  This 
multi-step scheme (Figure 10A) would mimic the natural chemistry of the module, 
except the PPTase would be required to recognize amino-CoA 11 and the adenylation 
domain would need to utilize an amine terminated phosphopantetheine arm as a 
nucleophile instead of the natural thiol substrate.    
Incubation of apo-EntF with amino-CoA 11, PPTase, 14C-radiolabeled serine 
and ATP at pH=9.0 in one pot resulted in formation of the desired construct (Figure 
11A).  The efficiency of the loading was quantified by precipitating the protein with 
trichloroacetic acid, washing and analysis by scintillation counting.  As compared to 
the natural system (apo-EntF, CoA, PPTase, 14C-labeled serine and ATP at pH=7.5), 
the yield of the loading was estimated to be ~95%.  Preparation of the seryl amide 
construct of EntF was also visualized using radioactive SDS-PAGE analysis.  As 
shown in Figure 10B, only in the presence of amino-CoA, 14C-serine, PPTase, MgCl2 
and ATP is a radioactive band evident that corresponds to the 142 kDa holo-EntF 
(lane 2).  In addition, the experiment demonstrates the hydrolytic stability of our 
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construct as the seryl-thioester EntF (lane 1) is hydrolyzed during the basic conditions 
of SDS-PAGE (pH=8.3) whereas the amide conjugate remains intact.23 
 
Figure 8: Analysis of loading amino-CoA analog onto PCP domain, demonstrated in NRPS EntF 
system. A) Schematic of the multistep enzymatic reaction of apo-EntF with amino-CoA 11, 
PPTase, ATP, and serine. B) Autoradiography SDS-PAGE analysis of 14C-radiolabeled seryl-
amide EntF. Lane 1: with coenzyme A, lane 2: with amino-CoA 11, and lane 3: no CoA or CoA 
analogue. All reaction mixtures contained PPTase, ATP, 14C-serine, and MgCl2. The band at ~140 
kDa corresponds to 14C-labeled EntF (the smaller band at ~ 90 kDa is a degradation product of 
EntF). 
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Materials and Methods 
General Procedures 
1H NMR spectra were recorded on a Varian 500, 400 or 300 MHz 
spectrometer.  Proton chemical shifts are reported in ppm (δ) relative to internal 
tetramethylsilane (TMS, δ 0.0 ppm) or with the solvent reference relative to TMS 
employed as the internal standard (D2O, δ 4.79 ppm).  Data are reported as follows: 
chemical shift (multiplicity [singlet (s), doublet (d), triplet (t), quartet (q), and 
multiplet (m)], coupling constants [Hz], integration).  13C NMR spectra were recorded 
on a Varian 500 (126 MHz) or 400 (100 MHz) spectrometer with complete proton 
decoupling.  Carbon chemical shifts are reported in ppm (δ) relative to TMS with the 
CDCl3 as the external standard (δ 77.26 ppm).  31P NMR spectra were recorded on a 
Varian 300 (121 MHz) spectrometer with complete proton decoupling employing an 
external standard (85% H3PO4, δ 0.0 ppm).  High resolution mass spectra were 
obtained at the Mass Spectrometry Facility of either Boston College (Chestnut Hill, 
MA) or the University of Illinois (Urbana-Champaign, IL).  The method of ionization 
is given in parentheses. 
Preparative HPLC was performed on a Shimadzu (LC-6AD) instrument 
equipped with a multiwavelength UV-Vis detector.  Preparative HPLC was carried 
out using a reverse-phase Vydac 218TP1022 C18 column (22 mm ID× 250 mm). 
Reagents and chemicals were purchased from the Sigma-Aldrich Chemical Company 
unless otherwise noted.  All the compounds synthesized were stored at -20ºC. For all 
the solid phase synthetic steps, the Kaiser test was employed to monitor the 
completeness of each step. 
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Kaiser test procedure. Reagent #1 was made by dissolving 250 mg of ninhydrin in 5 
mL ethanol. Reagent #2 was made by dissolving 4.0 g of phenol in 1.0 mL ethanol.  
Reagent #3 was made by dissolving 5 mg of KCN in one drop of water and added 5 
mL of pyridine (cloudy suspension).  A few sampled resin beads were transferred to a 
small glass test tube and 5 drops of reagent #1, 4 drops of reagent #2 and 1 drop of 
reagent #3 were added.  The suspension was swirled and heated at 100 ºC for 1 min.  
The presence of visibly blue beads indicated a positive test for free amines.  
 
Experimental Procedures 
 PMP-protected pantoic acid (5) was synthesized using the published 
procedure14.  
 
Amino-pantetheine (8)  Pantetheine analog 8 
was synthesized on solid support using trityl 
chloride polystyrene resin (Novabiochem, 
loading 1.6 mmol/g) in a solid phase synthesis vessel. The resin (1.00 g, 1.60 mmol) 
was swelled in DCM (8 mL) for 1 h before 1,2-diaminoethane (1.07 mL, 16.0 mmol) 
was added.  The suspension was agitated on a shaker for 12 h, then drained and rinsed 
with NMP (N-methyl-2-pyrrolidinone) (5×20mL) to give 1,2-diaminoethane-
functionalized resin.  A solution of FMOC-β-alanine (1.49 g, 4.80 mmol), PyBOP 
(2.50 g, 4.80 mmol), and DIPEA (1.67 mL, 9.60 mmol) in NMP (4 mL) was added to 
the resin and the suspension was agitated for 2 h, then drained and rinsed with NMP 
(5× 20 mL). The FMOC protecting group was removed by treating the resin with 20% 
(v/v) piperidine/NMP (20 mL) for 20 min, and then rinsed with NMP (5× 20 mL). A 
 
O O
PMP
HO2C
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solution of PMP-protected pantoic acid 5 (1.28 g, 4.80 mmol), PyBOP (2.50 g, 4.80 
mmol) and DIPEA (1.67 mL, 9.60 mmol) in NMP (4 mL) was added to the resin and 
the suspension was then agitated for 4 h. After rinsing with NMP (5× 20 mL) and 
DCM (5× 20 mL), the resin was treated with 15 mL of 5% (v/v) trifluoroacetic acid 
(TFA) and 2% (v/v) triethylsilane (TES) in DCM for 20 min to cleave the product 
from the resin. The resin was washed by 5% TFA in DCM (10 mL). The cleavage 
solution and wash solution were combined and concentrated in vacuo. The residue 
was redissolved in 10 mL 10% (v/v) TFA/H2O.  The aqueous solution was extracted 
twice with diethyl ether (10 mL), and then lyophilized to give 8 as a yellow oil. The 
product was further purified by preparative HPLC (9 mL/min flow rate; gradient: 0-
5min, 5% B; 5-25 min, 5-98% B, where A=0.05% TFA/H2O and B=0.05% 
TFA/CH3CN).  Chromatographs were monitored at 220nm and 8 was eluted at 11.2 
min.  Removal of solvents gave 8 as a colorless oil (combined purified yield 70%, 290 
mg).  1H NMR (D2O, 300 MHz) 3.94 (s, 1H), 3.49-3.43 (m, 5H), 3.35 (d, J = 11.1 Hz, 
1H), 3.10 (t, J = 5.9 Hz, 2H), 2.48 (t, J = 6.5 Hz, 2H), 0.88 (s, 3H), 0.85 (s, 3H).  13C 
NMR (D2O, 100 MHz) 175.1, 174.9, 75.9, 68.5, 39.4, 38.8, 37.0, 35.6, 20.7, 19.4.  
HRMS (ESI+) m/z Calcd for C11H24N3O4 262.1767, found 262.1768. 
 
Alternative route to synthesize amino-pantotheine 8. Pantothenate 14 (238 mg, 
1.00 mmol), diaminoethane 15 (334 µL, 5.00 mmol), and PyBOP (1.04 g, 2.00 mmol) 
were combined and dissolved in dry DMF (3 mL). DIPEA (696 µL, 4.00 mmol) was 
added, and the reaction was stirred for 5 h. Water (3 mL) was then added to the white, 
cloudy reaction mixture to dissolve the precipitate.  The mixture was extracted with 
EtOAc three times (total volume about 35 mL). The aqueous layer was dried by speed 
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vacuum to give light yellow oil. The resultant oil was aliquot and purified by 
preparative HPLC (8 mL/min flow rate; gradient: 0-5 min, 0% B; 5- 40 min, 0-30% B, 
where A=0.05% TFA/H2O and B=0.05% TFA/CH3CN; 8 eluted at 17.8 min) to yield 
8 (167 mg, 64%) as colorless oil. 
 
Enzymatic preparation of amino-coenzyme A (11).  
The genes encoding 
the PanK, PPAT, and 
DPCK enzymes were 
each amplified from E. 
coli genomic DNA using the following primers25: 
PanK: 
5’   GGGAATTCCATATGACCGCCAGAAACATGCTTATGAG 
3’   CGCGGATCCAAGCTTTTATTTGCGTAGTCTGACCTCTTCTACCG 
PPAT: 
5’   GTCTCTAGAGCTAGCATGCAAAAACGGGCGATTTATCC 
3’   CGCGGATCCAAGCTTCTACGCTAACTTCGCC 
DPCK: 
5’   GGGAATTCCATATGAGGTATATAGTTGCCTTAACGGGAG 
3’   CGCGGATCCAAGCTTTTACGGTTTTTCCTGTGAGACAAACTGC 
The PCR products were digested and ligated into the pET28a vector following a 
published protocol.25  The vectors were individually transformed and overexpressed 
in E. coli BL21(DE3) cells (Novagen). For each enzyme: cells were harvested by 
centrifugation at 3500 rpm for 20 min. The cell pellets were suspended in 40 mL lysis 
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buffer (20 mM Tris·HCl pH 7.5, 500 mM NaCl, 20 mM imidazole) and lysed by 
passing through a French Press cell at 1000 psi. The lysate was clarified by 
centrifugation at 10,000 rpm for 20 min. The supernatant was added 2 mL of Ni-NTA 
resin (Qiagen) suspension and incubated for 1 hr. The resin was washed with lysis 
buffer (4× 15 mL), and then the protein was eluted by 3× 15 mL elution buffer (20 
mM Tris·HCl pH 7.5, 500 mM NaCl, 250 mM imidazole). The first elution fraction 
for each enzyme was dialyzed against 1 L of 50 mM Hepes pH 8.0, 250 mM NaCl, 2 
mM MgCl2 buffer overnight at 4 ºC.  
 Enzymatic synthesis reactions were carried out following a similar procedure 
as reported25 with several modifications: the enzymatic reactions were performed in 
Tris·HCl buffer at pH 9.0 as no product was observed at pH 7.5; the reactions were 
run at 37 ºC with twice the amount of enzymes and ATP as reported and the reactions 
were terminated by trichloroacetic acid (TCA) precipitation (added 50% (w/v) TCA 
solution to give a 10% (w/v) final concentration, incubated for 20 min on ice, then 
centrifuged at 5,000 rpm for 10 min). The supernatant was lyophilized and the 
compound was purified on preparative reverse-phase C18 HPLC (9 mL/min; 0-5 min, 
0% B; 5-25 min, 0-5% B, where A=0.05% TFA/H2O and B=0.05% TFA/CH3CN; 11 
eluted at 25.5 min). Removal of solvent gave 11 as a white powder. The combined 
purified yield was 50% for 11. 1H NMR (D2O, 500 MHz) 8.69 (s, 1H), 8.45 (s, 1H), 
6.24 (d, J = 5.5Hz, 1H), 4.89-4.87 (m, 2H), 4.62 (br s, 1H), 4.29-4.27 (m, 2H), 4.04 (s, 
1H), 3.84 (q, J = 5.0 Hz, 1H), 3.66 (q, J = 5.0 Hz, 1H), 3.53-3.48(m, 4H), 3.14 (t, J = 
6.0 Hz, 2H), 2.51 (t, J = 6.5 Hz, 2H), 0.95 (s, 3H), 0.89 (s, 3H).  13C NMR (D2O, 126 
MHz) 175.4, 175.0, 150.1, 148.7, 144.9, 142.7, 118.8, 87.7, 83.8, 74.7, 74.3, 74.2, 
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71.9, 65.3, 39.4, 38.6, 37.0, 35.8, 35.6, 20.8, 19.1. 31P NMR (D2O, 121 MHz) 0.81, -
9.87, -10.30. HRMS (ESI+) m/z Calcd for C21H38N8O16P3 751.1619, found 751.1653.  
 
Oxy-pantetheine (12). Pantetheine analog 12 was 
synthesized on solid support using 2-chlorotrityl 
chloride polystyrene resin (Novabiochem, loading 1.4 mmol/g). To the pre-swelled 
(8mL DCM, 1 hour) resin (1.00 g, 1.4 mmol) was added a solution of N-FMOC-
ethanolamine (1.98 g, 7.00 mmol), pyridine (0.453mL, 5.60 mmol) in NMP (3 mL). 
The suspension was agitated on a shaker for 12 h, then drained and rinsed with NMP 
(5× 20 mL).  The FMOC protecting group was removed by treating the resin with 20% 
(v/v) piperidine/NMP (20 mL) for 20 min. The resin was then rinsed with NMP (5× 
20 mL) to give the glycinol-functionalized resin with a free amine. A solution of 
FMOC-β-alanine (1.30 g, 4.20 mmol), PyBOP (2.19 g, 4.20 mmol), and DIPEA (1.46 
mL, 8.40 mmol) in NMP (4 mL) was added to the resin and the suspension was 
agitated for 2 h, then drained and rinsed with NMP (5× 20 mL). The FMOC 
protecting group was removed by treating the resin with 20% (v/v) piperidine/NMP 
(20 mL) for 20 min, and then rinsed with NMP (5× 20 mL). A solution of compound 
5 (1.12 g, 4.20 mmol), PyBOP (2.19 g, 4.20 mmol) and DIPEA (1.46 mL, 8.40 mmol) 
in NMP (4 mL) was added to the resin and the suspension was then agitated for 4 h.  
After rinsing with NMP (5× 20 mL) and DCM (5× 20 mL), the resin was treated with 
15 mL of 5% (v/v) TFA and 2% (v/v) TES in DCM for 20 min to cleave the product 
from the resin. The resin was washed by 5% TFA in DCM (10 mL).  The wash and 
cleavage solutions were combined and concentrated in vacuo. The residue was 
redissolved in 10 mL 10% (v/v) TFA/H2O. The aqueous solution was extracted with 
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diethyl ether (2× 10 mL), and then lyophilized to give 12 as a yellow oil. The residue 
was further purified by preparative C18 HPLC as described for compound 8 (retention 
time of 13.5 min).  Removal of solvents gave 12 as a colorless oil (combined purified 
yield 50%, 180 mg). 1H NMR (D2O, 300 MHz) δ 3.93 (s, 1H), 3.59 (t, J = 5.6 Hz, 2H), 
3.48-3.44 (m, 3H), 3.33 (d, J = 11.4 Hz, 1H), 3.27 (t, J = 5.6 Hz, 2H), 2.46 (t, J = 6.6 
Hz, 2H), 0.87 (s, 3H), 0.83 (s, 3H).  13C NMR (D2O, 100 MHz) δ 175.0, 174.1, 75.9, 
68.5, 60.1, 41.7, 38.8, 35.7, 35.5, 20.7, 19.3.  HRMS (ESI+) m/z Calcd for 
C11H22N2O5Na 285.1426, found 285.1417.  
 
Oxy-CoA Analog (13). 
Oxy-pantetheine 12 was 
converted to oxy-
coenzyme A using the 
same protocol for 
amino-coenzyme A analog except that the pH 7.5, instead of pH 9.0, was used in 
enzymatic reactions. After purification on preparative HPLC using the same program 
for 11 (13 was eluted at 24.2 min), compound 13 was afforded as white powder in a 
yield of 65%. 1H NMR (D2O, 400 MHz) δ 8.66 (s, 1H), 8.41 (s, 1H), 6.20 (d, J = 5.6 
Hz, 1H), 4.85 (overlapping m, 2H), 4.58 (br s, 1H), 4.24 (br s, 2H), 4.01 (s, 1H), 3.86-
3.82 (m, 1H), 3.61-3.56 (overlapping t and m, 3H), 3.46 (t, J = 6.6 Hz, 2H), 3.27 (t, J 
= 5.2 Hz, 2H), 2.46 (t, J = 6.4 Hz, 2H), 0.92 (s, 3H), 0.80 (s, 3H).  13C NMR (D2O, 
100 MHz) δ 174.7, 174.1, 150.4, 148.6, 145.4, 142.3, 118.7, 87.5, 83.8, 74.4, 74.2, 
72.1, 65.3, 60.1, 41.7, 38.6, 38.5, 35.7, 35.6, 21.1, 18.5. 31P NMR (D2O, 121 MHz) δ 
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0.77, -9.82, -10.37. HRMS (ESI+) m/z Calcd for C21H37N7O17P3 752.1459, found 
752.1462. 
 
Quantitation of covalent incorporation of amino-CoA (11) and serine into apo-
EntF (Figure 10A). Overproduction and purification of EntF was accomplished as 
described by Gehring et al.27 Detection of the covalent incorporation of amino-CoA 
11 and serine into EntF was quantified using a trichloroacetic acid (TCA) 
precipitation radioassay30. The reaction mixture (200 μL final volume) included 75 
mM Tris·HCl (pH=9.0 for amino-CoA 11, or pH= 7.5 for blank control and CoA), 1 
mM tris-(2-carboxyethyl) phosphine (TCEP), 10 mM MgCl2, 10 mM ATP, 0.5 mM 
amino-CoA 11 (or CoA, or blank), 5 μM SVP PPTase (from Streptomyces verticillus), 
800 μM L-[14C]-serine (150 mCi/mmol) (PerkinElmer)/30 μM EntF. Apo protein was 
preincubated for 45 min at 37°C with SVP before addition of L-[14C]-serine and ATP. 
Reactions were initiated by addition of ATP, and incubated at 37°C for 30 min. 100 
μL reaction mixture was quenched with 0.8 mL 10% TCA with BSA (375 μg) added 
as a carrier. Precipitated proteins were centrifuged and washed three times with 10% 
TCA. The protein pellet was dissolved in 150 μL 1 M Tris base and the amount of 
incorporated [14C]seryl-N-phosphopantetheinyl quantified by liquid scintillation 
counting.  The 14C DPM results from blank control, CoA and amino-CoA 11 reactions 
are 386, 7535 and 7337, respectively.  
 
SDS-PAGE autoradiography analysis (Figure 10B). 20 μL of the reaction mixture 
from above was quenched by adding 10 μL (3X) SDS sample buffer prior to loading 
and electrophoresis on a 4-20% Tris-glycine gel (ISC Bioexpress). The gel was 
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stained with Coomassie blue, destained, and fixed in gel fixing buffer (10% methanol, 
5% acetic acid) prior to drying. The dried gel was exposed to a phosphorimaging K-
screen (Bio-Rad) for 7 days prior to imaging by Molecular Imager FX (Bio-Rad). 
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Chapter 3: 
Structural and mechanistic investigation of EntF peptidyl carrier-
thioesterase didomain with a phosphopantetheinyl analog 
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3.1 Introduction 
As outlined in chapter 1, thiol-templated oligomerization is a central element 
of the biosynthetic pathways to fatty acid (FA), polyketide (PK) and nonribosomal 
peptide (NRP) metabolites.1-3 The chemistry of activation, elongation and termination 
occurs on megadalton enzymes with a multidomain, modular organization.  During 
the synthetic pathways, building blocks and intermediates are covalently attached to 
the individual modules. The linkage is provided by a thiol-terminated 
phosphopantetheine (Ppant) prosthetic group that is derived from post-translational 
modification of a conserved serine residue on small protein carrier domains by 
reaction with coenzyme A (CoA).4,5 Small molecule carboxylic acid building blocks 
are coupled to Ppant as activated thioester intermediates.   
Recent structural characterization of multidomain protein assemblies has 
provided significant insight into FA/PK synthase and NRP synthetase structure and 
function.6-9 The small acyl or peptidyl carrier domain (ACP or PCP) with its attached 
Ppant plays a central role in the overall assembly line machinery by interacting with 
enzyme partners during multiple chemical steps. Structures of the fungal and 
mammalian megadalton, fatty acid synthases have been determined to atomic 
resolution, showing two distinct architectures for the iterative synthesis of fatty 
acids.6,7 The carrier domain/Ppant is often found to be disordered and not clearly 
evident in multidomain crystal structures. A notable exception is the 3.1Å structure of 
yeast fatty acid synthase where electron density for the ACP/Ppant is observed bound 
to the ketosynthase domain, but electron density for the Ppant prosthetic group was 
poor.10 In addition, the large distances (much greater than the length of the Ppant arm) 
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between the synthase active sites support a model where the ACP/Ppant domain is 
mobile and dynamic.   
Structural and functional analysis of several ACP domains from fatty acid and 
polyketide synthases reveal a common four-helix bundle structure with one helix in 
particular responsible for domain/domain interactions with partner proteins.11-13 The 
PCP domain of NRP synthetases adopts a similar helical structure as the ACPs from 
FA/PK synthases.14 NMR-based structural analysis of an isolated PCP domain from 
tyrocidine NRP synthetase showed distinct conformations dependent on the 
interacting partner in trans.15 Analysis of the excised apo-PCP-TE didomain construct 
of EntF, an enterobactin synthetase, illustrated that the apo-didomain fragment is 
mobile and adopts multiple conformations that include orientations that allow the 
Ppant arm to reach the active site of the thioesterase and others dependent on 
interaction of partner proteins in trans.16 The crystal structure of SrfA-C, a four-
domain (C-A-PCP-TE) termination module from surfactin NRP synthetase, was 
recently determined in its apo-form and provided valuable insight into the structure 
and domain organization of these assemblies.17  In this structure, the carrier domain is 
in a position to interact with the condensation domain. Biochemical analysis of PCP 
domains, along with similar experiments on ACP domains, indicate that one helix 
(α3PCP) plays a particularly significant role in interactions with partners.18,19 
The NRP natural product enterobactin is an iron-chelating siderophore used by 
E. coli to grow in iron-limited environments of vertebrate hosts.16 The enterobactin 
biosynthetic pathway from E. coli is a well-studied model system of NRP synthetase 
chemistry (Figure 1). The two modules (EntB/EntE and EntF) couple 2,3-
dihydroxybenzoic acid (DHB) and L-serine iteratively, followed by macrocyclization 
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producing the siderophore natural product.20,21 First, the dedicated 
phosphopantetheinyl transferase (PPTase), EntD, attaches the Ppant arm on to apo-
EntB and apo-EntF to produce the holo-form enzymes. Next, EntE, a stand-alone A 
domain, activates DHB and loads the aryl acid on to the Ppant of the PCP domain in 
the EntB module. The four domain holo-EntF module activates L-serine and couples 
the two building blocks attached to the PCP domain through the condensation (C) 
domain. The resulting DHB-Ser subunit is transferred to the conserved Ser of the 
thioesterase (TE) domain in the EntF module, releasing a free Ppant arm for the next 
cycle of condensation. Steps a-c (Figure 1) are repeated twice, forming a DHB-Ser 
linear trimer tethered to the PCP domain of the EntF module. Finally, the PCP and TE 
domain of EntF work in concert to execute the intramolecular cyclotrimerization 
forming the enterobactin trilactone.16 In general, NRP synthetases and PK synthases 
frequently cyclize the peptide or polyketide intermediate by use of an internal 
nucleophile to form macrocycles.  Many questions remain to be answered concerning 
the detailed chemical mechanism and control of cyclization catalyzed by TE domains.  
The enterobactin synthetase is a particularly interesting system that involves the 
selective formation of the cyclic trimer over other possible oligomers and cyclic 
oligomers.22   
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Figure 1: The biosynthesis of siderophore enterobactin.23 T (thiolation) domain is another term 
of PCP domain. The ICL domain of the EntB module is an isochorismate ligase that catalyzes the 
conversion of chlorismate to DHB, which is a preliminary step to the biosynthesis of enterobactin. 
The other steps are described in the text. 
An approach to gain insight into the structural basis for mobile carrier domains 
is to chemically alter the Ppant arm in order to direct assembly line complexes into a 
specific conformation (Figure 2a). Various chemical approaches have been developed 
involving synthetic coenzyme A analogs followed by use of a promiscuous 
phosphopantetheinyl transferase to load on the Ppant to carrier domains.24,25  The 
facile synthetic route to nonhydrolyzable amide analogs of coenzyme A thioesters, 
described in chapter 2, allows the production of designed carrier domain conjugates 
directed to different target domains of NRP synthetases.24  Similar approaches have 
recently been applied to PK synthases.25 
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Figure 2: Strategy to construct a conformationally restricted multidomain NRPS by 
coenzyme A analogs. a) CoA analogs designed to target the partner domains are loaded on the 
PCP domain of the multidomain NRPS using PPTase, forming a conformationally restricted 
complex. b) Peptidyl chains attached to the phosphopantetheinyl arms of the PCP domains 
undergo nucleophilic hydrolysis or cyclization catalyzed by thioesterase domain. c) The α-Chloro-
acetyl amide CoA analog is designed to target the Ser-Asp-His catalytic triad in the active site of a 
TE domain. 
To resolve the lack of detailed structural information on carrier domain and 
Ppant arm interaction with target enzymes, we solved the crystal structure of the PCP-
TE didomain construct from EntF with a designed Ppant arm. This specific atomic 
resolution complex with the Ppant arm in the active site of the thioesterase is the first 
multidomain NRP synthetase structure with a Ppant (or analog) arm in the active site.  
The structure provides detailed insight into the interactions between the Ppant arm 
and the TE domain and the domain/domain interactions in the didomain complex.  
This approach has the potential to gain detailed insight into additional multidomain 
constructs in NRP, PK and fatty acid synthase complexes.    
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3.2 The strategy for constructing a conformationally restricted PCP-TE 
didomain with the TE domain activity inhibited 
As an initial step to develop a general strategy to obtain conformationally 
ordered multidomain NRP synthetases, we chose the PCP-TE fragment from EntF.   
The didomain construct encompassed the final two domains of the four-domain EntF 
(domain organization: C-A-PCP-TE). This system is well-characterized biochemically 
and comparison with the recent NMR characterization of the apo-construct will 
provide the knowledge of the structural consequences of phosphopantetheinylation.16 
As mentioned, TE domains are responsible for cleaving Ppant-bound peptides off the 
NRPS machinery by hydrolyzing them to linear carboxylic acids or cyclizing them to 
macrocyclic products (Figure 2b).26,27 Although the specific mechanism of the 
cyclotrimerization catalyzed by the EntF TE domain (and related NRP synthetases) is 
not entirely established, the general chemistry of the TE domain is analogous to the 
nucleophilic mechanism of serine hydrolases.28 The active site of the TE domain 
contains a highly nucleophilic serine residue activated as part of a catalytic triad.28 
Electrophilic inhibitors commonly used to inhibit serine proteases also efficiently 
alkylate NRPS thioesterase domains.29,30 Taking advantage of this, an α-chloro-acetyl 
amide terminated CoA was designed and synthesized to target the active site of TE 
domain (Figure 2c).24  The CoA analog 2 was synthesized by coupling α-chloroacetic 
acid to amino-CoA (1) using PyBOP as the condensation reagent (Figure 3A).  Next, 
the α-chloro-CoA analog 2 was loaded on to the full-length apo-EntF using the 
PPTase Sfp from B. subtilis to verify the inhibition of the thioesterase domain. N,S-
diacetyl cysteamine (AcSNAC) was used as a simple substrate mimic for kinetic 
analysis of the TE domain activity.  The thioester AcSNAC was incubated with the 
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EntF conjugates, and TE-catalyzed hydrolysis of AcSNAC to N-acetylcysteamine and 
acetic acid was monitored using the spectrometric DTNB assay for free thiols.31  The 
results are plotted as initial velocity versus concentration of substrate in Figure 3B.  
The TE domain of holo-EntF shows proper concentration-dependent, Michaelis-
Menten kinetics (kcat= 2.5 min-1) for hydrolysis of the thioester substrate. In contrast, 
EntF loaded with 2 shows significantly diminished hydrolysis activity and 2 is a 
noncompetetive inhibitor.24  
 
Figure 3: Generation of a phosphopantetheinyl analog specific for thioesterase domains.  A) 
Synthesis of α-chloroacetyl CoA analog 2 from amino-CoA in a single step.  B)  Kinetic analysis 
of thioesterase activity for holo-EntF and the α-chloroacetyl amide EntF conjugate.  AcSNAC= 
N,S-diacetyl cysteamine. 
After confirming that the α-chloro-CoA analog 2 inhibits the TE domain 
activity, the inhibitor was applied to the crystallography of the EntF PCP-TE 
didomain. The EntF PCP-TE construct was cloned with a start in the A-PCP linker 
region (residue 965 of EntF) and purified to homogeneity.  The purified apo-PCP-TE 
construct was incubated with B. subtilis PPTase and 2 at 37oC. The conjugate was 
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purified and mass spectrometric analysis indicated a complete reaction to form the 
EntF-PCP-TE with Ppant analog (PA-PCP-TE) along with concomitant loss of 
chlorine. Although all efforts to crystallizing the apo- or natural holo-PCP-TE were 
unsuccessful, this construct readily crystallized. The structure of Ppant-PCP-TE 
analog was solved through single-wavelength anomalous dispersion (SAD) phasing of 
a selenomethionine derivative at 1.9 Å resolution.32 
 
3.3 The structure of EntF PCP-TE with the phosphopantetheinyl analog 
Overall structure 
The PA-PCP-TE conjugate crystallized in the P212121 space group with two 
protein molecules per asymmetric unit (Figure 4a). A short linker (residues 1044-1056) 
connects the secondary structural elements of the two domains. The TE domain 
belongs to the large α,β-hydrolase family of  enzymes.  Common to other TE domains 
involved in secondary metabolism and lipases, the mixed α,β-structure is ‘capped’ 
with an α-helical lid motif.28,33,34  The lid covers the catalytic triad and is proposed to 
bind the relatively large substrate and assist in the cyclization reaction.34-36  The two 
monomers observed in the crystal structure were very similar to each other (RMSDαc 
= 0.8 Å) and the only major difference was in the lid region where residues 1173-
1206 of the monomer B were not evident in the structure (Figure 4a).  The lack of 
clear density and assumed disorder in the lid region has been previously observed in 
most other NRPS TEs crystal structures without substrate.17,28,33 As monomer A is 
more complete than monomer B in the density maps (only residues 1176-1180 not 
modeled), the following discussion will focus specifically on this monomer (Figure 
4B).   The lid is composed of two α-helices (α5TE and α6TE) and includes an extended 
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region with a short helix (α4TE) inserted in the α, β-fold between α5ΤΕ and β5TE.  The 
catalytic triad is located on loops between helices and sheets and includes Ser1138, 
His1271 and Asp1165.  The PCP domain contains four α-helices along with a short 5-
amino-acid-turn helix.  The conformation of the PCP domain is in the A/H state as 
defined for alternate conformations of an isolated PCP domain from tyrocidine 
synthetase.15  The Ppant analog is covalently attached to the conserved serine residue 
(Ser1006) of the PCP domain and displays extensive interactions with the TE domain 
as discussed below. 
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Figure 4: The overall architecture of the PA-PCP-TE. a) Ribbon representation of the dimer 
observed in the asymmetric unit. Unordered regions of the monomers are shown as dashed lines. b) 
The closer view of monomer A. The catalytic triad in the active site of the TE domain is circled in 
purple. TE domain, PCP domain, and linker between the two domains are colored in blue, orange 
and red, respectively. The phosphopantetheinyl analog is represented as sticks with the color green 
for carbon, red for oxygen, blue for nitrogen and yellow for phosphorus.   
 
Structure of the Ppant analog arm and the interaction with the TE domain 
The Ppant analog was designed to form a stable co-complex of the PCP and 
TE domains, and elucidated structural details of the domain/domain and Ppant/protein 
interactions.  The density for the arm in the composite omit electron density map is 
contiguous with Ser1006 on the PCP domain (Figure 5a). A Fo-Fc model map of the 
structure without the phosphopantetheinyl arm confirms the position of the arm as 
there is clear density (shown in green color) in the region where the Ppant arm is 
supposed to be. The Ppant sits in a well-ordered channel in the TE domain leading to 
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the catalytic triad (Figrue 4b). The seryl-phosphate interacts with a series of ordered 
water molecules by hydrogen bonds and there is no obvious hydrated divalent cation 
adjacent to the phosphate despite 70 mM magnesium chloride included in the 
crystallization solution. A hydrophobic pocket forms interactions with the gem-
dimethyl section of the Ppant analog (Figure 5b).  Among the residues are Trp1079 
and Phe1077 located at the first α-helix (α1TE) and its adjacent loop, and Ile1213 from 
a lid helix (α6TE) of the TE domain. The Ala1074 and Ser1075 residues form 
hydrogen bonding interactions with the two amide carbonyls of the Ppant analog. 
Gln1080, stacking under one of the amides, is in van der Waals contact with the arm. 
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Figure 5: The structure of the Ppant arm and the interaction with the TE domain. a) The 
composite omit electron density map (blue, contoured at 1.5 σ) showing the area around the Ppant 
analog arm; the Fo-Fc model map (green, contoured at 2.2 σ) made from the model without the 
arm built in, confirming the existence of the Ppant arm. b) The residues interacting with the Ppant 
analog arm. c) Schematic representation of the residues interacting with the Ppant arm.  
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Domain/Domain interactions 
The PA-PCP-TE structure also revealed details of protein/protein interactions 
between the TE and PCP domains. As discussed, the carrier domain plays a central 
role in product flux through a NRP synthetase assembly line by interacting with 
multiple domains. Efforts to rationally engineer assembly line chemistry would 
benefit from structural information of carrier domain/partner domain interactions. 
However, the details are limited in the available crystal structures. The PCP domain in 
the structure presented here forms extensive interactions with the TE domain 
encompassing 2383 Å2 of surface area.  The PCP domain interacts primarily through 
α2PCP and α3PCP with α1TE and β1TE along with the two helices (α5TE and α6TE) in the 
lid of the TE domain (Figure 6).  The specific interactions are primarily hydrophobic 
in nature and include the previously described pocket near the gem-dimethyl of the 
Ppant, specifically Trp1079.  In addition, Leu1058 and Leu1060 (on β1TE) at the start 
of the TE domain interact with complementary hydrophobic residues Val1031 and 
Met1030 in α3PCP of the PCP domain. Interestingly, residue Arg1018 (on α2PCP) of 
the PCP domain forms hydrogen bonding interaction with residue Gln1201 on one of 
the helices (α5TE) of the TE lid, which may possibly help stabilize the compact 
conformation of the didomain. 
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Figure 6: The interface of the PCP domain and the TE domain. The residues of the PCP 
domain, TE α,β-domain, and TE lid region in the interface are colored orange, blue, and cyan, 
respectively; the secondary structural elements of these domains are colored in the same color 
system but lighter. The linker connecting two domains is colored in pink.  
Biochemical characterization of point mutants of full-length EntF. 
Based on the structure, residues of the TE predicted to be important for 
interaction with the Ppant arm and the PCP domain were analyzed by biochemical 
characterization of point mutants of the full length EntF four-domain enzyme.  The 
mutants were compared with the wild-type EntF in the ability to produce the natural 
product enterobactin from L-Ser and DHB in a reconstitution assay along with the 
other enzymes in the biosynthetic pathway.21 Trp1079 of the TE domain is in the 
hydrophobic pocket near the gem-dimethyl of the Ppant, and also participates in the 
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domain/domain interaction. The W1079A mutant showed complete loss of activity in 
the reconstitution assay. Residue Phe1077 is suggested to have hydrophobic 
interaction with the dimethyl group of the Ppant arm. Mutation of Phe1077 to Ala 
resulted in only 2% of the activity compared to wild-type EntF. Mutation of the 
residue Gln1080 that stacks under one of the amides forming van der waals contacts 
to Ala decreased the activity by ~50%. The results indicate that these residues 
observed to be interacting with the Ppant arm or involved in domain/domain 
interactions are critical to the overall production of the siderophore.   
The interaction of the phosphopantetheinyl analog arm and the active site of the 
TE domain 
As illustrated in Figure 7a, the catalytic triad is well-ordered in the active site 
of the TE domain and connected by two key H-bonds. The hydroxyl side chain of 
Ser1138 is properly positioned to attack the terminal carbonyl of the Ppant analog. 
The resulting oxyanion can be stabilized by hydrogen-bonding with the backbone 
amide hydrogens of Leu1139 and Ala1074 that form an oxyanion hole. The density 
connecting His1271 and the methylene carbon adjacent to the terminal amide of the 
Ppant analog in the Fo-Fc model map suggests that there might be two different 
conformations/structures of the inhibitor arm present in the complex (Figure 7b). α-
Cl-ketones are established inhibitors of serine hydrolases, capable of covalently 
modifying the histidine of the catalytic triad.37  It was anticipated that an α-Cl-amide 
would react through a similar electrophilic mechanism. LC-MS analysis of the protein 
loaded with the Ppant analog confirmed loss of chlorine. However, the mass was 
larger (by about 18 Da) than what is supposed to be if the Ppant is covalently linked 
to the histidine and suggested a terminal-hydrolyzed Ppant analog product is formed 
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after loss of chlorine. Based on these in vitro observations and analysis of the electron 
density maps, the α-Cl-acetyl-amide Ppant arm is proposed to undergo two possible 
reactions (Figure 7c). Ser1138 of the catalytic triad is predicted to attack the carbonyl 
group of the acetyl-Ppant arm and loss of chlorine produces a three member ring 
imtermediate 4. The reactive intermediate 4 is readily opened under the nucleophilic 
attack by water or His1271 to yield an α-hydroxy acetyl amide Ppant PCP-TE (5) or a 
cross-linked didomain construct (6) by forming a covalent bond to His1271, both with 
Ser1138 leaving. 
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Figure 7: The interaction of the phosphopantetheinyl analog arm and the active site of the 
TE domain. a) The interaction of the Ppant analog with the catalytic triad. The carbon, oxygen, 
and nitrogen atoms are labeled white, red and blue, respectively, with the exception that the carbon 
atoms of the Ppant arm are labeled green.  b) The composite omit electron density map (blue, 
contoured at 1.5 σ) and the Fo-Fc model map (green, contoured at 2.2 σ) around the arm and 
His1271. c) The mechanism of the inhibition of the α-chloro-amide Ppant analog on the TE 
domain. 
 
Comparison with the apo-EntF PCP-TE NMR structure  
The apo-EntF-PCP-TE structure solved by NMR showed that the didomain 
without the Ppant group is mobile and adopts multiple conformations.16 In 
comparison, the structure of PA-PCP-TE is more ordered and exhibits a more 
compact conformation, with extensive domain/Ppant and domain/domain interactions 
(Figure 8). All of the helices (especially α2PCP and α1PCP) in the PCP domain move 
significantly towards the TE domain and the helix α5TE in the lid region shifted closer 
to the PCP domain while the TE α,β-cores of the two structures were well overlaid. In 
the structure of PA-PCP-TE, the distance between the two Ser residues in the active 
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sites of the two domains is shortened to 16 Å from 19 Å in the apo structure. A helix 
(α3PCP) of the PCP domain and a β sheet (β1TE) of the TE domain at the domain 
interface in the PA-PCP-TE structure are not observed in the apo-structure. As 
mentioned previously, Met1030 and Val1031 are located on helix α3PCP forming 
hydrophobic interactions with two Leu residues on the β1TE sheet, which might 
contribute to the ordered secondary structural elements appearing in the PA-PCP-TE 
structure. The residue Met1030 is also suggested to be crucial for the in cis interaction 
with the TE domain by the previous combinatorial mutagenesis studies.38 The 
comparison with apo-EntF-PCP-TE indicates that the phosphopantetheinylation leads 
to enhanced interaction between the two domains. In addition, the loops (between 
β6TE and β7TE, β5TE and α5TE, and β7TE and α9TE) in the TE α,β-domain region, 
carrying the active site residues His1271 and Asp1165, are more structured than in the 
apo-structure by forming three short helices α4TE, α7TE, and α8TE, which may attribute 
to the interaction of the inhibitor arm with the substrate-binding site of the TE  
domain. 
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Figure 8: Comparison with the apo-PCP-TE structure solved by NMR. The TE domain in the 
apo-PCP-TE NMR structure (PDB code: 2roq, the 1st model of the composite structure; colored in 
orange) is superimposed with the TE domain from the PA-PCP-TE complex (colored in blue). The 
red circle shows the position of the active site Ser (mutated to Ala) in the apo-protein structure. 
Comparison with surfactin synthetase A-C, an apo-four-domain NRPS structure 
The apo-structure of the four-domain surfactin synthetase, SrfA-C, provides 
an overall picture of the multidomain organization of NRPS assembly lines.17 When 
superimposing the TE domains of PA-PCP-TE and SrfA-C, the TE α,β-sandwich core 
region is conserved between the two different TEs and the major difference is in the 
lid region (Figure 9). The lid in SrfA-C is very similar to the previously reported 
‘open’ state of the individual SrfTE domain, while the lid of the PA-PCP-TE 
conjugate is distinct from either of the ‘open’ or ‘closed’ form. Furthermore, the 
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distance between the active sites of the PCP and TE domain in the SrfA-C structure 
(43 Å) is much larger than that in PA-PCP-TE complex (16 Å). This is consistent with 
the previous conclusion that the PCP domain in SrfA-C is not in an orientation 
interacting with the TE domain, but with the accepter site of the C domain.17  
 
Figure 9: Comparison with the four-domain NRPS SrfA-C structure. The termination module 
of SrfA-C structure (PDB code: 2vsq) is superimposed onto the PA-PCP-TE. The domains are 
labeled in the same color with the ribbon presentation.The location of Ser (mutated to Ala) in the 
active site of the SrfA-C PCP domain is marked by a red solid circle. The difference in the lid 
regions of the two TE domains is circled in red. 
Sequence alignment with other PCP-TE didomain fragments 
Knowing that the Ppant arm analog interacts with the TE domain as well as 
between the two domains, we were curious whether these interactions are shared by 
other PCP-TE didomains. As illustrated in Figure 10, the alignment of EntF PCP-TE 
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sequence with those of other PCP-TE didomain fragments from surfactin, fengicyn, 
and tyrocidine NRPSs shows that most of the hydrophobic residues in the 
domain/domain interface discussed previously are either generously conserved or 
exchanged with other related hydrophobic residues, such as M1010 and M1030 from 
the PCP domain, L1058, L1060 and W1079 from the TE domain, and L1209 from the 
lid region. P1073 is absolutely conserved in all of the PCP-TE fragments, crucial in 
orienting the amide hydrogen of the backbone into the oxyanion hole. The residues 
aligned with R1018 (in PCP domain) which is suggested to form a hydrogen bond 
with Q1201 in the TE lid region are all hydrophilic residues. The alignment of F1077 
in the hydrophobic pocket with Phe, Tyr and Gln is not surprising, as the gem-
dimethyl group interacts with the benzylic carbon of the F1077 while remainder of the 
side chain points away from the hydrophobic pocket. From the alignment results, we 
may extend a similar in-cis interaction between the PCP and TE domain found in 
EntF to other NRPS PCP-TE didomains. 
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Figure 10: The protein sequence alignment of the EntF PCP-TE with other PCP-TE 
fragments. The sequence of EntF PCP-TE didomain is aligned with those of the termination 
modules of surfactin synthetase A-C, fengicyn synthetase and the tyrocidine synthetase III. The 
residues forming the secondary structures are underlined using the cartoon representations. The 
Asp-His-Ser triad is highlighted in green. The residues important for doman/domain or 
domain/Ppant interactions are circled in red, blue or purple if they are from PCP, TE α,β core or 
TE lid region, respectively. 
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3.4 Conclusions 
Presented is the 1.9 Å resolution structure of a ‘holo’-PCP/TE didomain from 
the termination module of a NRPS assembly line.  This work represents the first 
structure of a holo-NRPS multidomain fragment.  The crystallization and structure 
determination were feasible by employing a designed coenzyme A analog with an 
electrophilic group attached to the end and subsequently a Ppant analog loaded on to a 
truncated didomain construct. This allowed the construct to specifically form a 
compact conformation, mimicking the catalytic state of the enzyme bound to the 
natural substrate. The conformationally restricted didomain structure, for the first time, 
provides detailed insight into how the phosphopantetheinyl arm interacts with its 
partner enzyme and stabilizes domain/domain interactions. This methodology can be 
extended towards the crystallographic and mechanistic study of other multidomain 
NRP/PK synthetases.  
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Materials and Methods 
α-Chloroacetyl-amide 
CoA (2). Amino-CoA 1 
(2.9 mg, 3.8 μmol) was 
treated with α-chloroacetic 
acid (1.1 mg, 12 μmol), PyBOP (6.0 mg, 12 μmol), and DIPEA (4.0 μL, 23 μmol) in 
200 μL DMF/H2O (4:1) at r.t. for 2 h. The crude product was dried using speed 
vacuum and compound 2 was purified by preparative reverse phase HPLC (8 mL/min; 
0-3 min, 0% B; 3-40 min 0-10% B, where A=0.1% TFA/H2O; B= CH3CN; 2 eluted at 
29.7 min). Lyophilization gave 2 (2.3 mg, 80%) as white powder 1H NMR (D2O, 300 
MHz) 8.70 (s, 1H), 8.46 (s, 1H), 6.25 (d, J = 5.1 Hz, 1H), 4.90-4.88 (m, 2H), 4.62 (br 
s, 1H), 4.26-4.22 (m, 2H), 4.11 (s, 2H), 4.04 (s, 1H), 3.88-3.85 (m, 1H), 3.64-3.61 (m, 
1H), 3.48 (t, J = 6.3 Hz, 2H), 3.33-3.28 (overlapping m, 4H), 2.47 (t, J = 6.3 Hz, 2H), 
0.95 (s, 3H), 0.84 (s, 3H).  HRMS (ESI+) m/z Calcd for C23H38N8O17P3Cl 827.1329, 
found 827.1331. 
 
Preparation of α-chloroacetyl amide EntF (full-length) construct. Reaction 
mixture (2 mL final volume) included 75 mM Tris·HCl (pH=8.0), 1 mM TCEP, 10 
mM MgCl2, 0.5 mM α-chloroacetyl amide CoA 2, 5 μM SVP PPTase,  10 μM apo-
EntF.  The reaction was incubated for 45 min at 37°C to give the α-chloroacetyl 
amide EntF construct.  
 
DTNB assay for AcSNAC substrate hydrolysis catalyzed by EntF TE domain.           
The assay was performed by following the protocol described by Yeh et al.31 N,S-
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diacetylcysteamine (AcSNAC) was dissolved in DMSO (final volume of DMSO is 6 
μL in each assay). Freshly prepared solutions (200 μL each) of DTNB (2 mM), 
potassium phosphate (20 mM, pH=7.5), and increasing concentrations of AcSNAC 
(50-400 μM, as substrate inhibition was observed at higher concentrations), were 
mixed with enzyme EntF or α-chloroacetyl amide EntF construct (2 μM) at 24ºC.  
Generation of free thiol after thioester hydrolysis was assayed by reacting with DTNB 
producing TNB2-(ε412nm (TNB2-) =13,600 M-1·cm-1). The formation of 3-thio-5-
nitrobenzoate was continuously monitored in a UV-Vis spectrophotometer (412 nm) 
for 5 min. Background hydrolysis of AcSNAC was obtained by monitoring the same 
solution without enzyme and deducted from the initial velocities. 
 
Cloning and expression of EntF PCP-TE didomain construct. The gene encoding 
the EntF PCP-TE didomain was cloned from EntF plasmid DNA21 into the BamHI 
and XhoI sites of pET30a vector with a N-terminal Hig tag. The vector was 
transformed into BL21 (DE3) cells and grown in LB medium at 37 °C until an OD600 
of 0.6 was reached. The cell culture was then induced by addition of IPTG (50 μM) 
and incubated at 18 °C for 18 h. Cells were harvested and resuspended in lysis buffer 
(20 mM Tris·HCl pH 7.5, 500 mM NaCl). Resuspended cells were lysed by passing 
through a French pressure cell at 1000 psi. After centrifugation at 10,000 rpm for 20 
min, the supernatant was subjected to Ni-NTA affinity chromatography (QIAgen). 
The resin was washed with lysis buffer four times, and the protein was eluted using 
elution buffer (20 mM Tris·HCl pH 7.5, 500 mM NaCl, 250 mM imidazole), and then 
dialyzed against the dialysis buffer (100 mM NaCl, 20 mM Tris ·HCl pH 7.5, 1 mM 
βME). The protein was concentrated to 1mL, and 1 µL of  enterokinase (New 
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England Biolabs) was added. The mixture was incubated at r. t. for only 1 h 45 min to 
prevent undesired cleavage. Cleaved protein was separated from the uncleaved one by 
Ni-NTA affinity chromatography. Further purification was performed with a HiTrap-
Q (GE Biosciences) ion exchange column using a gradient of  0-80% buffer B over 30 
min at a flow rate of 2 ml/min (buffer A: 50 mM Tris·HCl pH 7.5, 1 mM βME; buffer 
B: 1 M NaCl, 20 mM Tris·HCl pH 7.5, 1 mM βME). 
For the production of SeMet-labeled EntF PCP-TE, we used thrombin to 
cleave the His-tag as SeMet protein wasn’t stable under the enterokinase cleavage 
condition described above. The gene encoding PCP-TE was cloned into NdeI and 
EcoRI sites of pET 28a vector. The vector was transformed into B834 (DE3), 
methionine auxotrophic E. coli cells (Novagen). M9 minimal medium was inoculated 
with 1/1000th volume of an LB-preculture that was centrifuged and resuspended in 
M9 medium. To 1 L of culture, all of the 20 amino acids (50 mg each) except 
methionine, 20% glucose (10 ml), 1M MgSO4 (2 ml), 2M CaCl2 (0.05 ml), 0.5% (w/v) 
thiamine soln (0.1 ml), seleno-methionine (60 mg) and FeSO4 (15 μM) were added. 
When an OD600 of 0.6 was reached, temperature was lowered to 15 °C and more 
seleno-methionine (30 mg) was added to the culture. After 15 min, IPTG (50 μM) was 
added to the culture and then the culture was incubated for another 18 h. Purification 
of SeMet-labeled protein followed the protocol described above with a few exceptions: 
All buffers contained 5 mM DTT except lysis buffer and elution buffer. All the 
buffers were degassed for 10 min with argon immediately before usage. The His-tag 
was cleaved by incubating with thrombin (7.5 U for 1 mL of concentrated protein 
solution in thrombin cleavage buffer (100 mM NaCl, 20 mM Tris·HCl 7.5, 2 mM 
CaCl2) at 4 °C overnight. 
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Preparation and purification of PA-PCP-TE construct. Preparation of PA-PCP-TE 
construct followed a similar procedure reported previously with some modifications.21 
The reaction mixture (5 mL) included 75 mM Tris·HCl (pH 8.0), 1 mM TCEP, 10 
mM MgCl2, 150 μM α-chloroacetyl amide CoA , 3 μM PPTase sfp from B. subtilis., 
30 μM apo-EntF PCP-TE/SeMet EntF PCP-TE. The reaction was incubated for 2 h at 
20°C and immediately purified on a HiLoad 16/60 SuperDex 200  (GE Biosciences) 
gel filtration column (gel filtration buffer: 100 mM NaCl, 20 mM Tris·HCl pH 7.5, 1 
mM βME or 5 mM DTT for SeMet protein) to give the PA-PCP-TE construct. 
Loading of the α-chloroacetyl amide phosphopantetheinyl arm was verified by LC-
MS. 
 
Crystallization and structure determination. Crystals of both native and SeMet-
labeled PA-PCP-TE were obtained by the hanging drop method at 20°C. Native 
protein (1.5 μL at 10 mg/ml in gel filtration buffer) was mixed with 1.5 µL of 
reservoir solution containing 24.5% (w/v) PEG 6K, 0.1 M Tris·HCl pH 8.5 and 70 
mM MgCl2. The crystallization reservoir solution for SeMet-labeled protein contained 
21% (w/v) PEG 8K, 0.1 M Tris·HCl pH 8.5 and 72.5 mM MgCl2. Crystals were 
observed after two days and were allowed to continue growth for several additional 
days. Crystals were soaked in  cryoprotectant solution (reservoir solution with 20% 
glycerol)  for 10 min and then flash frozen by liquid nitrogen. 
X-ray diffraction data of native PA-PCP-TE were collected at 1.9 Å resolution 
on the X25A beamline at the National Synchrotron Light Source (NSLS) at 
Brookhaven National Labs. A 2.2 Ǻ SAD data set of SeMet derivative was collected 
on the same beamline. All diffraction data were indexed, integrated and scaled using 
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the HKL2000 program39 in space group P212121 (a=69.401 Ǻ, b=90.361 Ǻ, 97.530 Ǻ, 
α=β=γ=90°). On the basis of examination of the asymmetric unit, two monomers are 
present (Matthews coefficient of 2.12 and 42% solvent content). From processing 
SAD data in hkl2map software40, 10 selenium sites were found.  Heavy atom phasing 
was carried out with the PHENIX software package41 using the selenium site 
information obtained from hkl2map. Initial electron density maps were calculated and 
a first model of EntF PCP-TE comprising 411 residues (including 226 residues 
without sidechains) out of 658 residues was obtained from PHENIX AutoBuild. The 
initial model contained a significant portion of TE domain and a very limited part of 
the PCP domain built in one monomer, while there was only a small part of the TE 
domain built in the other monomer, as well as some small fragments which were 
attributed to the symmetry-related protein molecules. The initial model was further 
built with the assistance of both non-crystallographic and crystallographic symmetry 
operations on the existing fragments using the program COOT42. The structure 
refinement was performed with COOT and the refinement programs in CNSsolve43 
until the refinement converged at a Rwork/Rfree of 20.9%/24.2% (Table S1). Sigma-
weighted simulated composite omit maps (CNS) were used to judge and verify 
structures throughout refinement. Figures were made using the program PYMOL44. 
 
Mutagenesis and biochemical assays. The EntF site-directed mutants F116A, 
W118A and Q119A were constructed by using QuikChange site-directed mutagenesis 
kit from Stratagene. PCR amplification was performed using the provided 
QuikChange Reaction Buffer, pfu, dNTP mix, DMSO, plasmid carrying EntF with 
his-tag, along with the following primers and their reverse compliments: F116A, 5’ 
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CAT CCT GCG TCC GGT GCT GCC TGG CAG TTC AG 3’; W118A, 5’ GCG 
TCC GGT TTT GCC GCG CAG TTC AGC GTG 3’; Q119A, 5’ CC GGT TTT GCC 
TGG GCG TTC AGC GTG CTC 3’. The PCR program consisted of an initial hold of 
95°C for 30 s followed by 16 cycles of 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 
20 min. The template DNA was digested with DpnI for 1 hour at 37 °C before 
transformation into XL1-blue cells. The mutagenesis products were confirmed by 
DNA sequencing.  
The plasmids carrying EntF (wild type and mutants), EntE and EntB genes 
were transformed into BL21 (DE3) E. coli cells. Cultures were grown at 37oC to an 
OD600 of 0.6 and then induced with 500 μM IPTG and harvested 3 h later.  Protein 
purification followed the same procedure as for native EntF PCP-TE without His-tag 
cleavage. Holo-EntB was prepared by following the reported procedure21 and purified 
by gel filtration as described above. After purification, desired proteins were dialyzed 
against 25 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 5 mM DTT, and 10% glycerol and 
stored at -80oC.  
The enterobactin formation assay was performed as described and modified as 
follows: Incubate 200 nM apo-EntF (w.t. or mutants) and 200 nM Sfp in 10 mM 
MgCl2, 75 mM Tris-HCl pH 7.5, 0.5 mM TCEP and 500 µM CoASH for 2h at r. t. 
Incubate 10 μM holo-EntB and 600 nM EntE in 10 mM MgCl2, 75 mM Tris-HCl pH 
7.5, 0.5 mM TCEP, 2 mM L-Ser, 1 mM DHB and 20 mM ATP for 10 min at r. t. 
Reaction was initiated by mixing equal amount of these two solutions together and 
incubating at 37oC. The reaction mixture was quenched by 1M HCl at certain time 
points, extracted with ethyl acetate, concentrated, dissolved in 30% ACN/H2O and 
then analyzed by HPLC using a C18 reverse phase column (VyDAC, cat. 
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No.218TP54). Enterobactin was eluted using a 17-70% gradient of Buffer B over 30 
min at a flow rate of 1 mL/min (A=0.05% TFA/H2O and B=0.05% TFA/MeOH), 
monitoring at 254 nm (Figure 11). The peak corresponding to enterobactin was 
collected and verified by mass spec. 
 
Figure 11: The activity assays of the EntF mutants. A) HPLC traces of the reconstitution assay 
using wild-typle (WT) EntF as an example. The peak corresponding to product enterobactin 
increases, while the starting material DHB peak decreases over the time. B) The production of 
enterobactin is plotted against the time in the reconstitution assays with EntF wt and mutants. 
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Chapter 4: 
An isosteric substrate mimic as a mechanistic probe of DpgC: 
A cofactor-independent dioxygenase in the vancomycin biosynthesis. 
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4.1 Introduction 
The vancomycin and teicoplanin (Figure 1) classes of glycopeptide antibiotics are 
used to treat life-threatening gram-positive bacterial infection and have traditionally been 
reserved as antibiotics of the last resort. 1,2 The rigidifying crosslinks in the amino acid 
side chains of  the heptapeptide backbone generate an unusual cup-like shape (Figure 
2).3,4 The structural geometry of vancomycin is vital for the antibiotics to bind to the N-
Acyl-D-Ala-D-Ala precusor of  the peptidoglycan layer of bacterial cell walls, thereby 
interrupt the cell wall biosynthesis of the bacterial pathogens.5 
 
Figure 1: Vancomycin and teicoplanin containing the non-proteinogenic amino acid Dpg 
(highlighted in yellow). 
The heptapeptide backbone of vancomycin is synthesized by a nonribosomal 
peptide synthetase assembly line that is comprised of seven modules.6 Incorporated into 
the backbone are two non-proteinogenic amino acids, (S)-4-hydroxyphenylglycine (Hpg) 
and S-3,5-dihydroxyphenylglycine (Dpg) (Figure 1).  These two uncommon amino acids 
are also found in other vancomycin family members (telcoplanin, chloroeremomycin, and 
102 
 
bahlimycin) and contribute to the structural complexity that impart unique biological 
activity.6  
 
Figure 2: Vancomycin hydrogen-bonded to N-Acyl-D-Ala-D-Ala precursor (left); space filling 
model of vancomycin and D-Ala-D-Ala termini (right). 
The biosynthetic pathway of Dpg is composed of five enzymes DpgA, DpgB, 
DpgD, DpgC and HpgT in the producer actinomycetes bacteria (Figure 3). 7,8  DpgA  is a 
Type III PKS that builds one hydrated dihydroxyphenylacetyl-CoA (DPA-CoA) from 
four malonyl-CoA molecules  (Figure 4a). Characterized as dehydratases, DpgB and 
DpgD assist the cyclization of the DpgA product to produce DPA-CoA which is the 
substrate for DpgC (Figure 4b). DpgC performs a four-electron oxidation and cleaves the 
thioester bond on DPA-CoA to convert the substrate to 3,5-dihydroxyphenylglyoxylate 
(DPGx).8 The same transaminase responsible for the last step in the biosynthesis of Hpg 
then acts on DPGx yielding Dpg.9 
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Figure 3: Biosynthetic pathway of Dpg.7 
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Figure 4: Proposed mechanism of (a) DpgA and (b) DpgB/DpgD.8 
As mentioned above, DpgC carries out two reaction steps: first, oxidation of the 
α-methylene group to a keto group using only molecular oxygen and then cleavage of 
thioester to release a DPGx free acid and CoA. The direct reaction of molecular oxygen 
with organic compounds is formally a disallowed spin-forbidden transformation. To 
activate triplet oxygen, bound flavin cofactors or transition metals are utilized by most of 
the characterized oxygenase.10 DpgC is a unique enzyme as it is independent of any 
cofactor or metal, which makes it quite interesting to investigate its novel mechanism. 
There are two possible mechanisms proposed for the DpgC chemistry by Tseng et al. 
(Figure 5). 7 Both of the mechanisms start with deprotonation of α-methylene and 
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formation of a carbanion at C2 position. In one of the mechanisms, transfer of O2 is 
proposed to occur through attack of a peroxy anion on the C1-thioester carbonyl, resulting 
in nonhydrolytic cleavage of the thioester bond through a putative α-peroxylactone 
intermediate (Figure 5, upper pathway).  The weak O-O single bond and the acidity of the 
Cα-H bond in the unstable intermediate favors the generation of the final product DPGx.  
Tseng et al7 also suggested a second potential mechanism with a Baeyer-Villiger type, 
Criegee rearrangement of hydroperoxide (Figure 5, lower pathway). A hydroxide ion is 
produced from the migration of the C-H bond and the intermediate attacks back on the 
thioester carbonyl releasing CoA.  Confirmed by 18O2 incubation experiment, both of the 
atoms from a single oxygen molecule are incorporated into the α-ketone and carboxylate 
of the product DPGx and thereby, DpgC is a dioxygenase. 
 
Figure 5: Two proposed mechanisms for DpgC. The oxygen atoms deriving from O2 are filled in for 
clarity. 7 
Prior to this work, questions of substrate recognition, binding of oxygen molecule 
and activation of molecular oxygen in the unique dioxygenase DpgC were mostly 
unanswered. An atomic-resolution crystal structure of DpgC would be useful in 
answering these questions. The X-ray crystal structure of DpgC without any 
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substrate/inhibitor bound was determined in our lab11, but this structure did not provide 
details of the unusual chemistry. The natural substrate, DPA-CoA is not suitable for co-
crystallization experiment as it would hydrolyze and be released from the active site in 
the crystallization conditions. Therefore, we applied the coenzyme A analog chemistry 
described in chapter 2 to synthesize an isosteric substrate mimic of DpgC. Through the 
co-crystal structure of DpgC with the synthesized inhibitor, we have developed a clear 
picture of the active site of DpgC. Not only does the study present detailed mechanistic 
information on the unprecedented oxidation chemistry, it also provides general 
knowledge of the biosynthesis of a key non-proteinogenic amino acid in antibiotic 
vancomycin. 
 
4.2 Design and synthesis of a hydrolytically stable substrate mimic of DpgC 
As mentioned, DpgC catalyzes the four-electron oxidation at the α-carbon of the 
substrate DPA-CoA (1), resulting in cleavage of the thioester bond to form DPGx (2) 
(Figure 6a). To probe the chemistry of DpgC active site, an analog where cleavage of the 
thioester bond is prevented is desired. This substrate mimic could bind the active site 
through CoA functionality. An amide version of DPA-CoA analog, 3 is such a good 
substrate mimic as an amide is isosteric to a thioester with the exception of a hydrogen 
atom (Figure 6b). DPA-NH-CoA is stable, as the amide is more resistant to hydrolysis 
compared to the thioester. Formation of the acyl-thioester enolate is predicted to be the 
first step in DpgC reaction (Figure 5).7 Replacing the thioester with an amide would also 
block the deprotonation at the 2-carbon position and prevent the subsequent downstream 
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chemistry (Figure 6b).12 Protonation at α-C in the amide analog would make it close to 
the real substrate binding state and provides a true picture of substrate-bound active site. 
 
 
Figure 6: Rational design of the substrate mimic. a) Transformation of the natural substrate DPA-
CoA (1) to the product DPGx (2) catalyzed by DpgC. b) Substrate mimic DPA-NH-CoA (3) does not 
undergo deprotonation forming enolate under DpgC. 
The chemical synthesis of the natural substrate DPA-CoA (1) and its amide 
analog, 3 is illustrated in Figure 7. Methyl-3,5-dihydroxyphenylacetate(4) was 
hydrolyzed to the corresponding acid, 5.   Condensation of the acid with CoA 6 or amino-
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CoA 7 (the synthesis was describled in Chapter 2) using PyBOP yielded the desired 
DPA-CoA (1) or the amide analog of DPA-CoA, 3 (~95% yield).13 
  
Figure 7: Synthesis of natural substrate DPA-CoA 1 and an isosteric substrate analog for DpgC, 
DPA-NH-CoA 3 . 
 
4.3 Evaluation of the isosteric substrate analog, DPA-NH-CoA 
The substrate analog DPA-NH-CoA, 3 was first tested for its hydrolytic stability. 
We subjected 3 to the enzyme DpgC for 4 hours at room temperature, pH 7.5, under the 
enzymatic conditions used for DpgC.8  Under these conditions, DpgC fully converts  the 
substrate DPA-CoA to Dpgx and free CoA (Figure 8A).  HPLC and MS analysis of the 
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products of the reaction with subtrate analog showed the amide analog, 3 was recovered 
unchanged under these conditions (Figure 8B). 
 
Figure 8: Assays of DpgC with DPA-CoA orr DPA-NH-CoA. A) DPA-CoA without enzyme added 
(control trace); DPA-CoA was fully converted to Dpgx and free CoA after incubation with DpgC 
(assay trace). B) Analog 3 without enzyme added (control trace).  Analog 3 after incubation with 
enzyme DpgC (assay trace) remained unchanged. 
The substrate analog 3 was next evaluated for its ability to inhibit the enzyme 
DpgC.  Activity assays were carried out using the DTNB [5, 5’-dithiobis(2-nitrobenzoic 
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acid)] reporter assay, which quantifies the production of free thiol groups through 
formation of a spectroscopically active disulfide.8 To determine the kinetic parameters of 
DpgC with its natural substrate DPA-CoA, a solution of DTNB, Tris·HCl pH 7.5 and 
increasing concentrations of DPA-CoA were incubated with DpgC.  The reactions were 
monitored in a UV-Vis spectrophotometer (412 nm) for 5 min. The observed initial rate 
of absorbance increase was converted to initial reaction velocity V0. 1/V0 was plotted as a 
function of 1/[S] according to Lineweaver and Burk equation (equation 1)14 (Figure 9).  
The measured KM was 4.7 μM and the kcat was 7.8 min-1.  
1 K M 1 1
V0 Vmax [S] Vmax
= + (1)
 
 
Figure 9: Lineweaver-Burk plot: determination of KM and kcat  of natural substrate DPA-CoA. 
The activity of DpgC in the presence of DPA-NH-CoA was then evaluated. As 
illustrated in Figure 10, DPA-NH-CoA, 3 acts as an efficient inhibitor of DpgC with a 
measured IC50 of 5.3 µM at a constant substrate concentration of 5.0 µM.  Further 
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experimental analysis established the Ki of the inhibitor to be 2.7 µM according to the 
method of Dixon (equation 2, 3, Figure 11)15, which is in close agreement with the IC50 
results.  The similarity between the KM of the natural substrate and the Ki of our inhibitor 
is consistent with 3 acting as a competitive inhibitor and a good substrate mimic. 
3
 
Figure 10: Inhibition of DpgC activity with substrate analog 3. 
1 [S] + K M K M
V0 Vmax[S] Vmax[S] K i
= + (2)[I]
[S] + K M = [I] = x-intercept (3)
K M
K i-
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Figure 11: Dixon Plot: determination of Ki for 3. 
 
4.4 The co-crystal structure of DpgC bound to DPA-NH-CoA 
Paul Widboom had worked out apo-DpgC crystallization and solved the structure 
using SAD-phasing techniques. The structure of the apo-enzyme was incomplete as 
numerous disordered regions were present, particularly close to the predicted active site 
(Figure 12, left structure). Elisha Fielding carried out the co-crystallization of DpgC with 
the designed synthetic inhibitor DPA-NH-CoA (3) and solved the co-complex structure 
using molecular replacement with the incomplete apo-structure (Figure 12, right 
structure). The active site is well-ordered and the inhibitor 3 is clearly evident in the 
electron density maps (Figure 13). 13 
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Figure 12: The comparison of the apo-DpgC structure (disordered in proximity to the predicted 
active site) and the inhibitor-bound DpgC structure (the active site is well-ordered). 
The coenzyme portion of the inhibitor DPA-NH-CoA binds the active site in an 
extended conformation with the adenosine moiety bent back.13 The 3,5-dihydroxyphenyl 
ring binds in a well-defined pocket. The 3-hydroxyl forms a hydrogen bond with Glu189 
and has an unusual interaction with the face of Arg 254 (Figure 14). The 5-hydroxyl is 
hydrogen bonding to an ordered water molecule W141 (red sphere). The backbone amide 
hydrogens of Ile 235 and Gly 296 are positioned in a favorite geometry to stabilize the 
predicted thioester enolate, forming an ‘oxyanion hole’ (Figure 15). An ordered water 
molecule (W258, Figure 15) is close to the pro-R hydrogen on the benzylic carbon for 
assisting the predicted deprotonation of the substrate.  This water molecule W258 is in a 
hydrogen bonding network with water W147 and Gln299.  
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Figure 13: Composite omit electron density map (contoured at 1.7 σ) showing the region around 
the inhibitor, molecular oxygen and catalytically related waters.13 
 
 
Figure 14: Recognition of the 3, 5-dihydroxyphenyl ring of the inhibitor DPA-NH-CoA. 
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Figure 15: The active site of DpgC with the bound inhibitor DPA-NH-CoA. Residues Gly296 and 
Ile 235 comprise the ‘oxyanion hole’.  
Based on the structural information of the substrate-bound DpgC and biochemical 
assays of DpgC mutants, the mechanism of DpgC chemistry is proposed as in Figure 17. 
13 In the first step, the pro-R proton on α-carbon of the thioester is deprotonated by 
ordered water W258. Resulted thio-enolate oxyanion is stabilized by backbone amides of 
residues Ile 235 and Gly296. Molecular oxygen, present in a hydrophobic pocket, is 
properly positioned to react with the substrate. Facilitated by Arg254 and Glu189, an 
electron from the substrate is transferred to triplet oxygen, generating a conjugated 
superoxide/radical cation pair which can collapse to give the peroxide intermediate. As 
the thioester is still located in the activating oxyanion hole, the intermediate can collapse 
to form 1,2-dioxetanone with the release of CoA. The α-hydrogen of the resulted 1,2-
dioxetanone is in an analogous position to the proR hydrogen of the substrate 
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deprotonated in the first step. The similar deprotonation leads to the formation of the 
product, DPGx. 
 
Figure 16: Proposed mechanism for DpgC chemistry.  
In conclusion, our designed substrate analog DPA-NH-CoA was synthesized 
using the coenzyme A chemistry described in chapter 2. It was characterized to be a 
competitive inhibitor and stable under DpgC turnover conditions.  Co-crystallization of 
DpgC with this substrate mimic solved the problem of disorder in the active site of the 
apo-structure.  The inhibitor-bound enzyme structure provided a detailed picture of the 
DpgC active site, allowing us to propose a mechanism for the unique chemistry of this 
cofactor-independent dioxygenase. This work is essential for understanding the 
biosynthetic pathway of the important vancomycin and teicoplanin family antibiotics, as 
well as the general mechanism of enzymatic oxygen activation.  
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Material and Methods 
DPA-NH-CoA (3).   
 
 
 
 
 
The acyl-CoA amide analog 3 was synthesized by coupling of 3,5-dihydroxyphenylacetic 
acid (5) with amino-CoA (7).  To prepare 5, methyl 3, 5-dihydroxyphenylacetate (4) (150 
mg, 0.823 mmol) was added to 5.0 mL of 2 M aqueous NaOH and stirred at room 
temperature.  After 1.5 h, the reaction was acidified to pH 1.0 with 2 M HCl.  The orange 
solution was flash frozen with N2 (l) and lyophilized overnight. The resulting reddish 
orange powder was taken up in MeOH and passed through a plug of silica gel.  
Concentration of the fractions under vacuum gave 5 as a white powder (110 mg, yield 
80 %).  The acid 5 was stored in the dark at -20ºC under argon.  The coupling of 7 with 5 
was done following the published procedure for the synthesis of acyl-coenzyme A 
thioesters16, with two modifications: 2.5 eq of 5 and 2.5 eq of PyBOP were used to 
couple 9.0 mg of 7;  The crude product was purified by preparative HPLC (8 mL/min; 0-
3 min, 0% B; 3-40 min 0-20% B, where A=0.1% TFA/H2O; B= CH3CN; 3 eluted at 22.2 
min), monitoring at 260 nm.  Removal of the solvents by lyophilization  gave 3 as a white 
powder (10.3 mg, yield 95%). 1H NMR (D2O, 500 MHz) δ 8.71 (s, 1H), 8.45 (s, 1H), 
6.31 (overlapping m, 2H), 6.24 (overlapping m, 2H), 4.93 (overlapping m, 2H), 4.66 (br s, 
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1H), 4.34 (br s, 2H), 4.07 (s, 1H), 3.92-3.90 (m, 1H), 3.69-3.67 (m, 1H), 3.44 
(overlapping m, 4H), 3.33 (overlapping m, 4H), 2.42 (t, J = 6.0 Hz, 2H), 0.99 (s, 3H), 
0.89 (s, 3H).  13C NMR (D2O, 126 MHz) δ 174.9, 174.8, 174.3, 157.1, 150.0, 148.6, 
144.8, 142.7, 137.7, 118.8, 108.3, 101.5, 87.8, 83.8, 74.6, 74.3, 74.2, 72.1, 65.3, 42.5, 
38.9, 38.8, 38.6, 35.6, 21.0, 18.8.  31P NMR (D2O, 121 MHz) δ 0.74, -9.90, -10.34. 
HRMS (ESI-) m/z Calcd for C29H42N8O19P3 899.1779, found 899.1825.  
 
3,5-Dihydroxyphenylacetyl-coenzyme A thioester (DPA-CoA, 1).  
 
 
 
 
 
The synthesis of DPA-CoA followed the previously reported protocol16 with the 
following modification: 2.5 eq of 5 and 2.5 eq of PyBOP were used.  The crude product 
was purified by preparative C18 HPLC (8 mL/min; 0-3 min, 0% B; 3-40 min 0-20% B; 
where A = 0.1% TFA/H2O; B = CH3CN; DPA-CoA eluted at 31.8 min), monitoring at 
260 nm.   
 
Assays for DpgC with DPA-CoA (1) and with DPA-NH-CoA (3). 
Cloning, overexpression and purification of the enzyme DpgC followed a published 
protocol8.  
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1) DpgC enzymatic assay. 
DPA-CoA (1) or DPA-NH-CoA (3) (0.5 mM) was incubated with DpgC (2.5 μM) at 24 
ºC (100 μL, 20 mM Tris·HCl pH 7.5) for 4 h.  The reaction was quenched with 1 μL TFA 
and products were analyzed by analytical C18 HPLC (1 mL/min; 0-3 min, 2% B; 3-43 
min, 2-22% B, where A=0.05% TFA/H2O and B=0.05% TFA/CH3CN), monitoring at 
260 nm.  
2) Kinetic inhibition assays with 3. 
Kinetic analysis for DpgC was done by using the DTNB [5,5’-dithiobis(2-nitrobenzoic 
acid)] reporter assay as described8 with one modification: the concentration of DpgC was 
0.4 μM.  
a) KM and kcat determination. 
To determine the kinetic parameters of DpgC for substrate DPA-CoA, a freshly prepared 
solution of DTNB (1 mM), Tris·HCl (250 mM), and increasing concentrations of DPA-
CoA was mixed with DpgC (0.4 μM) at 24ºC (1 mL).  The reactions were monitored in a 
UV-Vis spectrophotometer (412 nm) for 5 min. The observed initial rate of absorbance 
increase was converted to initial reaction velocity V0 (ε412nm=13,600 M-1·cm-1). 1/V0 was 
plotted as a function of 1/[S] according to Lineweaver and Burk equation (equation 1).  
Our measured KM was 4.7 μM and the kcat was 7.8 min-1 (similar to literature values: KM= 
6 μM, kcat= 10 min-1). 8 
1 K M 1 1
V0 Vmax [S] Vmax
= + (1)
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b) The Ki determination of analog 3. 
Inhibition assays were performed using the same conditions as above with increasing 
concentrations of analog 3 at a constant concentration of substrate DPA-CoA ([S] = 5 μM, 
10 μM or 40 μM).  1/V0 was plotted as a function of concentration of 3 according to the 
method of Dixon (equation 2, 3).15 
1 [S] + K M K M
V0 Vmax[S] Vmax[S] K i
= + (2)[I]
 
Ki was calculated from the x-intercept as follows:  
[S] + K M = [I] = x-intercept (3)
K M
K i-
          
The Ki was established to be 2.7 ±0.3 μM and the plots indicate competitive inhibition.15 
c) IC50 determination ([S] = 5 μM ). 
The relative enzyme activity (initial velocity with inhibitor over initial velocity without 
inhibitor, when [S] = 5 μM) was plotted as a function of concentration of inhibitor 3. The 
concentration which inhibited 50% of the enzyme activity was taken as the IC50. The IC50 
of 3 is 5.3 μM when the substrate concentration is 5.0 μM as diagrammed (main text, 
Figure 11). 
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Chapter 5: 
Synthesis of the inhibitors for adenylation domains and efforts toward 
the crystallization of adenylation-peptidyl carrier protein didomains. 
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5.1 Introduction 
As illustrated in chapters 2 and 3, synthetic amino-CoA (1) is a useful tool for the 
generation of a variety of stable amide analogs of phosphopantetheinylated non-
ribosomal peptide synthetases (NRPSs).  In this chapter, adenylation (A) domains are 
targeted for tethered, specific inhibitors. Adenylation domains are in charge of selecting, 
activating and loading module-specific amino acids on the phosphopantetheine (Ppant) 
arm as aminoacyl thioesters.  Amino-CoA terminated as various aminoacyl amides were 
our initial synthetic target.  These CoA analogs can then be added to apo-NRPS proteins, 
forming aminoacyl amide conjugates using promiscuous phosphopantetheinyl transferase 
(PPTase) similar to that previously described(Figure 1). A domains are responsible for 
most of the binding and specificity of the amino acid building blocks in NRPS 
chemistry.1,2 A nonhydrolyzable amino acid tethered arm is predicted to bind specifically 
in the A domain as a product-like inhibitor in a multidomain assembly. As discussed in 
Chapter 1, an apo-NRPS assembly line is inherently disordered: flexibility between 
individual domains allows for proper substrate trafficking, and is likely an integral part of 
the overall mechanism. The inherent flexibility between domains in NRPS increases the 
difficulty of crystallization of these multi-domain proteins. Inhibitor-tethered CoA 
analogs, by directing the arm into the specific active site, may freeze the assembly into a 
single conformation and favor crystallization.  
We have applied our CoA analogs strategy to the crystallization attempts of three 
discrete adenylation-thiolation (A-T) didomain NRPS proteins (CmaA, SyrB1 and 
truncated FscH) and a four-domain NRPS protein EntF (introduced in Chapter 2 and 
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Chapter 3) with their corresponding inhibitor-tethered phosphopantetheinyl arm. The 
background information of enzymes CmaA, SyrB1 and FscH will be introduced, 
respectively, as following.  
 
Figure 1: The construction of stable aminoacyl amide conjugates of holo-NRPS modules. A) The 
general strategy for loading stable aminoacyl CoA analogues onto NRPS synthetases by using the 
enzyme PPTase. Aminoacyl amide conjugates are designed to target the adenylation domain. B) 
NRPS-conjugated phosphopantetheinyl analogues are synthesized from amino-CoA (1). 
CmaA is a discrete A-T didomain enzyme involved in the biosynthesis of 
coronatine (COR, Figure 2a), a unique phytotoxin.3 COR is a hybrid non-ribosomal 
peptide/polyketide and contributes to virulence in several host-pathogen interactions in a 
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variety of plant species.4,5 COR is comprised of a polyketide-derived carboxylic acid, 
coronafacic acid and an unusual cyclopropyl amino acid, coronamic acid (CMA) which 
are covalently linked by an amide bond.6,7  
 
Figure 2: Biosynthetic pathway of CMA and coronatine.8 
CMA is derived from the non-proteinogenic L-allo-isoleucine via NRPS 
methodology (Figure 2b).8 The A domain of CmaA activates L-allo-isoleucine and 
attaches it on to the Ppant arm of the CmaA T domain. The L-allo-Ile group is then 
transferred by CmaE to a stand-alone T domain, CmaD. Next, CmaB, a unique non-haem 
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Fe2+ halogenase, chlorinates the γ-position of aliphatic carbon of the substrate 
regiospecifically. The enzyme CmaC deprotonates the α-H and cyclizes CmaD-bound 6-
chloro-allo-Ile group to form a cyclopropyl ring, which is followed by thioester 
hydrolysis to produce free CMA. CmaA is the first example of an A domain specialized 
for the (2S, 3R) stereochemistry of L-allo-isoleucine.3 
 
Figure 3: Biosynthesis of 4-Cl-L-Thr, a key component of syringomycin E.9 
SyrB1 is one of the two biosynthetic enzymes responsible for generating 4-Cl-L-
threonine, a key component of syringomycin E (Figure 3).10 The nine-residue cyclic 
lipodepsipeptide syringomycin E is a phytotoxin produced by Pseudomonas syringae pv. 
syringae B301D.11 4-Cl-L-Thr at residue nine is a vital moiety as loss of the chlorine 
leads to a 3-fold decrease of biological activity.12 Similar to that described for CmaA, the 
A domain of SyrB1 catalyzes the activation of L-threonine, the precursor of 4-Cl-L-Thr, 
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and installs it on the T domain. Next, SyrB2, a member of nonheme Fe(II) α-
ketoglutarate-dependent enzyme superfamily, carries out a chlorination on the 4-positon 
of the threonyl-S-SyrB1 (Figure 3). SyrB1 provides an indispensable scaffold for the 
recognition by SyrB2.12 4-Cl-L-Thr-S-SyrB1 is a putative immediate donor to the 
octapeptidyl-S-SyrE, which forms the final nine-residue cyclic peptide syringomycin E 
(Figure 3).10  
 
 
Figure 4: Structures of fuscachelins A-C.13 
FscH is an NRPS enzyme involved in the biosynthetic assembly line of the 
fuscachelin natural products, whose structures were recently elucidated by Eric Dimise in 
our group(Figure 4).13 Fuscachelins are siderophores produced by the thermophilic 
actinomycete Thermobifida fusca, a widely studied model organism for thermostable 
cellulases, a major degrader of plant cell walls.14-18 The proposed biosynthetic pathway 
for fuscachelin A contains multiple NRPS modules (FscC/F, FscG, FscH and FscI) with 
132 
 
several unusual aspects (Figure 5).13 FscH is composed of a condensation (C) domain, an 
A domain and a PCP domain, responsible for installing the building block L-serine. The 
C domain of FscI catalyzes two different couplings during this pathway. The first 
coupling is between 2,3-dihydroxybenzoic acid (DHB)-Arg-Gly-Gly-Ser bound to FscH 
and δ-nitrogen of L-Nδ-hydroxyornithine (L-HOOrn) tethered to the PCP domain of FscI. 
The second couples Dhb-Arg-Gly-Gly attached to FscG, and the α-nitrogen of the same 
L-HOOrn on the FscI PCP domain. This sequence skips module FscH, which makes this 
pathway an example of limited nonlinear NRPS assembly line chemistry.19 After the 
tandem couplings, the thioesterase of FscI performs the cyclization generating the unique 
10-membered lactone ring of fuscachelin A. The biosynthetic pathway of fuscachelin A 
represents several atypical features exhibiting the flexibility of NRPS assembly line 
machinery to build biologically active nature products.13 
 
Figure 5: Biosynthesis of fuscachelin A.13 
Due to the significance of these biosynthetic proteins and their general pathways 
introduced above, we would like to investigate the catalytic mechanism involved in these 
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enzymes. By crystallizing didomain or multi-domain NRPS proteins with the A-domain-
inhibitor-tethered phosphopantetheinyl analogs, we hope to obtain the detailed structural 
information of the A domains as well as the interaction between A domain and PCP 
domain in the reactive form. 
 
5.2 Synthesis of aminoacyl amide CoAs as A-domain-specific inhibitors and 
the inhibition characterization 
A group of aminoacyl amide CoAs has been synthesized targeting a variety of 
different NRPS A domains using an FMOC-based coupling methodology as illustrated in 
Figure 6.20 Commercially available FMOC-protected amino acids are coupled to amino-
CoA, 1 (see chapter 2) using PyBOP/DIPEA condensation chemistry.  The resulting CoA 
analogs are stable to both acidic and basic deprotection conditions leading to the desired 
compounds.   This simple protocol is useful for coupling a suitably protected acid, 
generating a wide range of nonhydrolyzable acyl-CoA analogs.  
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Figure 6: The synthesis of a variety of amino-acyl amide CoAs from amino-CoA (1).  
To demonstrate the inhibition of A domains using these aminoacyl amide CoAs, a 
seryl amide protein conjugate designed to inhibit the enzymatic function of the A domain 
of EntF was evaluated. If the seryl amide phosphopantetheinyl EntF is acting as a 
product-like analog as proposed, inhibition of the A domain should be observed by 
analysis of the active site kinetics. The ATP/pyrophosphate exchange assay is commonly 
used to measure the capacity of A domains to activate amino acids with ATP (Figure 7).21 
The adenylation domain function of seryl amide EntF was compared to the wild type 
holo-EntF. Both enzymes (holo-EntF and seryl amide EntF) were incubated with varying 
concentrations of serine, along with ATP and 32P-pyrophosphate, under established 
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conditions.21 As illustrated in a Lineweaver-Burk plot22 (Figure 8), the seryl amide EntF 
displayed a significant decrease in A domain activity.20 As expected, the KM for substrate 
serine with the inhibitor conjugate is higher compared to holo-EntF.  The kcat (and Vmax) 
of both enzymes are approximately the same.  This result is consistent with the seryl-
tethered arm acting as a competitive inhibitor of adenylation domain. 
 
Figure 7: ATP-pyrophosphate exchange assay. The adenylation domain in NRPS catalyzes a 
reversible reaction converting amino acid and ATP to aminoacyl-AMP and pyrophosphate. The 
“ * ”on phosphorus indicates 32P labeled. 
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Figure 8: Kinetic analysis of the adenylation-domain activity of seryl amide EntF compared to wild 
type holo-EntF. The A domain activity was measured at various concentrations of serine, and kinetic 
parameters were determined by plotting in the manner of Lineweaver and Burk.  
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5.3 Synthesis of aminoacyl-AMP mimics: sulfamoyl adenosine inhibitors 
As mentioned previously, adenylation domains activate amino acids as 
aminoacyl-AMP intermediates, and then transfer them on to the phosphopantetheinyl arm 
of a PCP domain releasing AMP (Figure 9A). Based on the mechanism, Ferreras et al. 
developed an inhibitor, salicyl-AMS (5’-O-[N-salicylsulfamoyl] adenosine) which targets 
salicylate adenylation enzymes.23 This inhibitor mimics the aminoacyl-AMP intermediate 
by replacement of the reactive phosphate with a stable sulfamoyl group (Figure 9B).  
This strategy has been successfully extended to develop potent inhibitors for other 
adenylation enzymes.24-27 Therefore, we applied this methodology to design AMS 
inhibitors targeting A domains of interest. Hopefully, these AMP-intermediate-mimic 
inhibitors can assist the crystallization of the A-T didomains and multi-domain NRPSs 
mentioned above. 
As illustrated in Figure 10, the corresponding aminoacyl-sulamoyl inhibitors for 
NRPSs CmaA, SyrB1 and EntF were synthesized using a published protocol with minor 
modifications.24 Briefly, the 2’and 3’-hydroxyl groups of adenosine are first selectively 
protected with 2,2-dimethoxypropane using p-toluenesulfonic acid as a catalyst. 2’,3’-
isopropylideneadenosine, 7 is treated with sodium hydride and sulfamoyl chloride 
subsequentially forming the versatile intermediate sulfamoyl adenosine (AMS, 8). Most 
of the Boc-protected amino acids, with side chain properly protected, are commercially 
available as N-hydroxysuccinimide esters, which are more reactive than the 
corresponding acids. The couplings of aminoacyl-N-hydroxysuccinimide esters with 
AMS are assisted by DBU, followed by one deprotection step with TFA to yield 
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aminoacyl-AMS products.  Boc-Thr(OBu)-OSu is not commercially available, but can be 
generated by the DCC-facilitated coupling  of the Boc-Thr(OBu)-OH acid with N-
hydroxysuccinimide. All the compounds were synthesized in milligram scale and purified 
by preparative reverse phase HPLC. 
 
Figure 9: Design of aminoacyl-sulfamoyl adenosine inhibitors for adenylation domains. A) A 
domains activate amino acids as aminoacyl-AMP intermediate and transfers them onto 
phosphopantetheinyl arm of PCP domain releasing AMP. B) Stable aminoacyl-sulfamoyl adenosine 
(AMS) inhibitors mimic the aminoacyl-AMP intermediates in A domain reactions. 
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Figure 10: Synthesis of adenosine-sulfamoyl (AMS) analogs. 
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5.4 Efforts toward crystallization of three A-T didomains (CmaA, SyrB1 and 
truncated FscH) and multi-domain NRPS EntF. 
With both aminoacyl amide CoA and sulfamoyl adenosine inhibitors in hand, we 
then attempted the co-crystallization of the A-T didomains and muti-domain NRPS EntF 
with both classes of inhibitors, respectively. The plasmids including CmaA(with His-tag), 
SyrB1(with His-tag) and EntF (no His-tag) genes, were kindly provided by the 
Christopher Walsh lab at Harvard Medical School. The plasmid of the truncated FscH A-
T domain with His-tag was obtained by cloning from a plasmid containing the full length 
FscH. The enzymes CmaA, SyrB1, FscH(A-T) and EntF were over-expressed in E. coli 
cells in apo-forms by adding 15 µM Fe(II) to inhibit the activity of the endogenous E. 
coli PPTase EntD. The apo-forms of CmaA, SyrB1 and FscH (A-T) were lysed and 
purified by Ni-NTA, ion exchange and size exclusion columns. EntF without an affinity 
tag was purified by ion exchange, hydrophobic, and size exclusion chromatography. 
SyrB1, EntF and FscH were homogenous after gel filtration column, while CmaA had a 
light lower band attributed to proteolysis to form A domain which could not be separated 
by chromatography (Figure 11).   
Synthetic aminoacyl amide CoA analogs were next loaded onto apo-A-PCP 
enzymes by the PPTase sfp from B. subtilis.28 For convenience, Ile-NH-CoA was used 
for CmaA, as L-isoleucine showed comparable Km with the natural substrate L-allo-
isoleucine for His-CmaA.3 The enzymes tethered with A-domain-specific inhibitors were 
seperated from sfp and other small molecules in the reaction by passing through gel 
filtration column again. The inhibitor-tethered enzymes were then screened for 
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crystallization conditions with Hampton Screen kit at both 20 ◦C and 4 ◦C. Unfortunately, 
after extensive trials, no conclusive crystal hit was found under these conditions.  
 
Figure 11: SDS-PAGE on the fractions of apo-SyrB1, CmaA, EntF and FscH (A-T) from size 
exclusion column purification. The same protein molecular weight marker was used as a standard for 
all of the four proteins and the first, second and third protein bands are with a molecular weight of 175 
kDa, 83 kDa and 60 kDa, correspondingly. A) apo-SyrB1; B) apo-CmaA; C) apo-EntF; D) apo-FscH 
(truncated A-T). 
The synthetic AMS inhibitors were then employed in co-crystallization screening 
with both apo- and holo-form of SyrB1, CmaA, FscH (A-T) and EntF at 20 ◦C and 4 ◦C. 
Holo, Ppant loaded proteins were thought to better mimic the actual active form when 
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bound to AMS inhibitors. The holo-form proteins were obtained by over-expression in E. 
coli cells which were co-transformed with a PPTase (sfp)-encoding plasmid. However, no 
crystal hit was found in any of the Hampton Screen conditions for either apo- or holo-
form.  
 
Figure 12: Synthetic scheme of aminoacyl-phosphopantetheine analogs. 
The intrinsic interdomain flexibility in multi-domain NRPSs, as mentioned at the 
beginning of this chapter, may be a factor in the extreme difficuly seen in attempts to 
crystallize multi-domain NRPSs, even when bound to an A domain inhibitor. In the 
future, we could try to co-crystallize a truncated A domain with an aminoacyl-
phosphopantetheine analog (Figure 12), which mimics the product of an A domain in the 
absence of a T domain. This analog has been successfully applied to the crystallization of 
LmnQ29, a stand-alone A domain in biosynthesis of leinamycin, by Rebecca Goldstein in 
our group.30 The synthesis of aminoacyl-phosphopantetheine analogs, as illustrated in 
Figure 12, starts from adding phosphate group to amino-pantetheine (the synthesis is in 
chapter 1) with E. coli CoA biosynthetic enzyme PanK. The coupling with FMOC-
protected amino acids using PyBOP/DIPEA followed by deprotection gives the 
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aminoacyl-phosphopantetheine analogs. This class of inhibitors should be useful as 
general mechanistic probes of NRPS A domains. 
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Materials and Methods 
Valyl-amide CoA (2). 
Amino-CoA 1 (5.0 mg, 6.7 
μmol) was treated with N-
FMOC-Valine (5.7 mg, 17 
μmol), PyBOP (8.7 mg, 17 μmol), and DIPEA (5.8 μL, 33 μmol) in DMF/H2O (350 μL, 
2.5:1) for 3 h. The protecting group was removed by treating the solution with 40% (v/v) 
piperidine/DMF (350 µL) for 30 min. After lyophilized, the crude product was treated 
with 8 mL of DCM/H2O/TFA (50:50:0.1). The aqueous layer was lyophilized again and 
compound 2 was purified by preparative reverse phase HPLC (8 mL/min; 0-3 min, 0% B; 
3-40 min 0-30% B, where A=0.1% TFA/H2O; B= CH3CN; 2 eluted at 20.4 min). 
Removal of solvent gave 2 (3.2 mg, 65%) as white powder. 1H NMR (D2O, 400 MHz) 
8.66 (s, 1H), 8.42 (s, 1H), 6.21 (d, J = 5.6 Hz, 1H), 4.86-4.84 (m, 2H), 4.59 (br s, 1H), 
4.25-4.21 (m, 2H), 4.01 (s, 1H), 3.84-3.80 (m, 1H), 3.72 (d, J = 6.4 Hz, 1H), 3.63-3.59 
(m, 1H), 3.50-3.41 (m, 2H), 3.38-3.24 (overlapping m, 4H), 2.44 (t, J = 6.4 Hz, 2H), 
2.19-2.10 (m, 1H), 0.98 (d, J = 6.8 Hz, 6H), 0.92 (s, 3H), 0.83 (s, 3H). HRMS (ESI-) m/z 
Calcd for C26H45N9O17P3 848.2146, found 848.2125. 
 
Seryl-amide CoA (3).  
Amino-CoA 1 (3.3 mg, 
4.4 μmol) was reacted 
with N-FMOC-(O-
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trityl)-serine (5.0 mg, 8.8 μmol), PyBOP (4.6 mg, 8.8 μmol), and DIPEA (3.1 μL, 18 
μmol) in DMF/H2O (300 μL, 4:1) for 2 h. Protecting groups were removed by treating the 
solution with  40% (v/v) piperidine/DMF (300 µL) for 30 min and then slowly adding 
50%(v/v) TFA/H2O until the solution turned orange. When lyophilized, the crude product 
was treated with 6 mL of DCM/H2O/TFA (50:50:0.1). The aqueous layer was lyophilized 
again and compound 3 was purified by preparative reverse phase HPLC (8 mL/min; 0-3 
min, 0% B; 3-40 min 0-50% B, where A=0.1% TFA/H2O; B= CH3CN; 3 eluted at 16.9 
min). Removal of solvent gave 3 (1.7 mg, 50%) as white powder. 1H NMR (D2O, 300 
MHz) 8.66 (s, 1H), 8.41 (s, 1H), 6.22 (d, J = 5.7 Hz, 1H), 4.85-4.83 (m, 2H), 4.66 (br s, 
1H), 4.24-4.22 (m, 2H), 4.08-4.05 (m, 1H), 4.00 (s, 1H), 3.94 (dd, 1H), 3.93 (dd, 1H), 
3.71-3.66 (m, 1H), 3.61-3.56 (m, 1H), 3.49-3.41(m, 2H), 3.38-3.24 (overlapping m, 4H), 
2.44 (t, J = 7.0 Hz, 2H), 0.91 (s, 3H), 0.83 (s, 3H). MS (ESI+) m/z Calcd for 
C24H43N9O18P3 838.19, found 838.3. 
 
Isoleucyl-amide CoA (4). 
The synthesis of Ile-NH-
CoA (4) followed the 
same procedure with Val-
NH-CoA (2). 1H NMR (D2O, 300 MHz) 8.66 (s, 1H), 8.42 (s, 1H), 6.21 (d, J = 8.0 Hz, 
1H), 4.86-4.82 (m, 2H), 4.59 (br s, 1H), 4.25-4.21 (m, 2H), 4.01 (s, 1H), 3.81-3.85 (m, 
1H), 3.79 (d, J = 5.6 Hz, 1H), 3.63-3.59 (m, 1H), 3.48-3.44 (m, 2H), 3.36-3.26 
(overlapping m, 4H), 2.44 (t, J = 6.4 Hz, 2H), 1.97-1.84 (m, 1H), 1.54-1.40 (m, 2H), 0.94 
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(d, J = 7.2 Hz, 3H), 0.92 (s, 3H), 0.89 (t, J = 7.4 Hz, 3H), 0.83 (s, 3H). MS (ESI-) m/z 
Calcd for C27H48N9O17P3 862.2, found 862.4.  
 
Threonyl-amide CoA (5) 
The synthesis of Thr-NH-
CoA (5) followed the 
same procedure with Ser-
NH-CoA (3). 1H NMR (D2O, 400 MHz) 8.64 (s, 1H), 8.40 (s, 1H), 6.19 (d, J = 4.8 Hz, 
1H), 4.85-4.82 (m, 2H), 4.56 (br s, 1H), 4.24-4.20 (m, 2H), 4.10-4.07 (m, 1H), 3.98 (s, 
1H), 3.82-3.78 (overlapping m and d, 2 H), 3.62-3.58 (m, 1H), 3.45-3.40(m, 2H), 3.35-
3.23 (overlapping m, 4H), 2.42 (t, J = 6.4 Hz, 2H), 1.23 (d, J = 6.8 Hz, 3H), 0.89 (s, 3H), 
0.81 (s, 3H). MS (ESI-) m/z Calcd for C25H43N9O18P3 850.2, found 849.7.  
 
Tyrosyl-amide 
CoA (6) 
The synthesis of 
Tyr-NH-CoA (6) 
followed the same 
procedure with Val-NH-CoA (2). 1H NMR (D2O, 400 MHz) 8.64 (s, 1H), 8.38 (s, 1H), 
7.17 (d, J = 6.8 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 6.18 (d, J = 4.8 Hz, 1H), 4.86-4.82 (m, 
2H), 4.60 (br s, 1H), 4.29-4.24 (m, 2H), 4.01 (s, 1H), 3.81-3.85 (m, 1H), 3.69-3.62 
O
N
H OH
O
N
H
OH
N P
O
P
O
HO HO OO
O
O
OH
N
P
OH
O OH
N
N
N
NH2
OOH
NH2
O
N
H OH
O
N
H
OH
N P
O
P
O
HO HO OO
O
O
OH
N
P
OH
O OH
N
N
N
NH2
O
NH2
HO
146 
 
(overlapping m 6H), 3.43-3.50 (overlapping m, 4H), 2.41 (t, J = 6.4 Hz, 2H), 0.92 (s, 3H), 
0.85 (s, 3H). MS (ESI-) m/z Calcd for C30H45N9O18P3 912.2, found 911.8.  
 
Synthesis of sulfamoyl adenosine (AMS, 8) and aminoacyl-AMS analogs (9-11). The 
synthesis of sulfamoyl adenosine (AMS, 8) and aminoacyl-AMS analogs (9-11) followed 
a published procedure24. 
 
Isoleucyl-AMS (9). 
1H NMR (D2O, 400 MHz) 8.55 (s, 1H), 8.42 (s, 1H), 
6.17 (d, J = 4.8 Hz, 1H), 4.76-4.73 (m, 1H), 4.54-4.50 
(m, 1H), 4.45-4.36 (m, 3H), 3.72 (d, J = 3.6 Hz, 1H), 
2.03-1.94 (m, 1H), 1.45-1.38 (m, 1H), 1.26-1.13 (m, 1H), 0.96 (d, J = 6.8 Hz, 3H), 0.85 
(t, J = 7.2 Hz, 3H).  MS (ESI+) m/z Calcd for C16H26N7O7S 460.2, found 460.4.  
 
Seryl-AMS (10). 
1H NMR (D2O, 400 MHz) 8.53 (s, 1H), 8.41 (s, 1H), 
6.17 (d, J = 5.6 Hz, 1H), 4.72-4.70 (m, 1H), 4.56-4.49 
(m, 1H), 4.42-4.33 (m, 3H), 3.98-3.95 (m, 2H), 3.92-
3.89 (m, 1H). MS (ESI+) m/z Calcd for C13H20N7O8S 434.1, found 433.6.  
 
Threonyl-AMS (11). 1H NMR (D2O, 400 MHz) 8.55 
(s, 1H), 8.42 (s, 1H), 6.18 (d, J = 4.8 Hz, 1H), 4.78-
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4.76 (m, 1H), 4.53-4.51 (m, 1H), 4.44-4.35 (m, 3H), 4.29-4.23 (m, 1H), 3.66 (d, J = 4.4 
Hz, 1H),  1.32 (d, J = 8.8 Hz, 3H). MS (ESI+) m/z Calcd for C14H22N7O8S 448.1, found 
447.7.  
 
Overexpression and purification of SryB1, CmaA, FscH (AT) and EntF. The 
plasmids including CmaA (with His-tag), SyrB1 (with His-tag) and EntF (no His-tag) 
genes were kindly provided by Walsh lab at Harvard Medical School. The plasmid of 
truncated FscH A-T domain with His-tag was obtained by cloning from intact FscH 
plasmid into the NdeI and HindIII sites of vector pET28a.  The plasmids were 
transformed into BL21 (DE3) cells and grown in LB medium at 37 °C until an OD of 0.6 
was reached. The cell culture was then induced by IPTG (50 μM) and incubated at 15 °C 
for 18 h. FeSO4 (15 µM) was added to the culture at the beginning of inducing to inhibit 
the activity of E. coli endogenous PPTase EntD. Cells were harvested and resuspended in 
lysis buffer (20 mM Tris·HCl pH 7.5, 500 mM NaCl). Resuspended celles were lysed by 
passing French Press at 1000 psi. After centrifuging at 10,000 rpm for 20 min, the 
supernatant of SyrB1, CmaA and FscH was subjected to Ni-NTA affinity 
chromatography (QIAgen). The protein was washed by lysis buffer four times, eluted by 
elution buffer (20 mM Tris·HCl pH 7.5, 500 mM NaCl, 250 mM imidazole), and then 
dialyzed against buffer (100 mM NaCl, 20 mM Tris ·HCl pH 7.5, 1 mM βME). Further 
purification was performed with a HiTrap-Q (GE Biosciences) ion exchange column 
using a gradient of  0-80% buffer B over 30 min at a flow rate of 2 ml/min (buffer A: 50 
mM Tris·HCl pH 7.5, 1 mM βME; buffer B: 1 M NaCl, 20 mM Tris·HCl pH 7.5, 1 mM 
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βME). Corresponding ractions were then loaded on a HiLoad 16/60 SuperDex 200 (GE 
Biosciences) gel filtration column (gel filtration buffer: 100 mM NaCl, 20 mM Tris·HCl 
pH 7.5, 1 mM βME) to give high-purity proteins. For EntF (no His-tag), the purification 
was done by passing ion exchange, hydrophobic and gel filtration columns 
subsquencially. 
 
Preparation of holo-NRPS enzyme and aminoacyl amide NRPS enzyme constructs. 
The reaction mixture (5 mL final volume) included 75 mM Tris·HCl (pH = 7.5), 1 mM 
TCEP, 10 mM MgCl2, 150 μM CoA or aminoacyl amide CoA, 300 μM PPTase sfp, 30 
μM apo-NRPS enzyme.  The reactions were incubated for 1.5 h at 20 °C and purified by 
passing gel filtration column to yield aminoacyl  amide NRPS or holo-NRPS.  
 
Crystallization screening of SyrB1, CmaA, FscH (A-T) and EntF with inhibitors. For 
aminoacyl amide NRPS conjugates, the purified proteins (1 µL, at 10 mg/ml) were mixed 
with the solution (1 µL) from High-throughput Hampton Research Crystal Screen Kit 
(HR2-130) at 4 ◦C or 20 ◦C. For co-crystallization with AMS inhibitors, the enzymes 
were incubated with AMS inhibitor (2 mM, dissolved in gel filtration buffer) for 1 h 
before setting up the screen. 
 
Assay for adenylation reaction catalyzed by holo-EntF (or seryl amide EntF 
construct) A domain: ATP-[32P]PPi exchange assay. ATP-pyrophosphate exchange 
was assayed following the procedure described by Rusnak21 with several modifications: 
149 
 
Reaction mixtures included (final volume 100 μL): 10 mM MgCl2, 5 mM DTT, 75 mM 
Tris-HCl (pH7.5), 5 mM ATP, 1 mM sodium [32P]pyrophosphate (~5 Ci/mol) and 20 nM 
holo-EntF or seryl amide EntF construct. The assay was initiated by the addition of 
increasing concentrations of serine and incubated at 24 °C for 5 min, respectively (each 
concentration was assayed in duplicate). Reactions were quenched by the addition of 0.5 
mL of a charcoal suspension (1.6% (w/v) activated charcoal, 0.1 M tetrasodium 
pyrophosphate, 0.35 M perchloric acid), and then centrifuged. The liquid was removed, 
and the charcoal pellet was washed three times with 0.8 mL of washing solution (0.1 M 
tetrasodium pyrophosphate, 0.35 M perchloric acid). The pellet was then suspended in 
0.6 mL of water and added to 3 mL of scintillation fluid; 32P incorporation into ATP was 
quantified by liquid scintillation counting. 
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